{"gene":"MS4A1","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1988,"finding":"Molecular cloning of CD20 (B1/MS4A1) cDNA revealed a predicted protein lacking an N-terminal signal sequence, containing three extensive hydrophobic (transmembrane) regions, a highly charged C-terminal cytoplasmic domain, and no homology to other known proteins. In vitro translation produced a single 33 kDa protein. CD20 was shown to be strongly phosphorylated after CDw40 stimulation.","method":"cDNA cloning, in vitro translation, immunoprecipitation, Northern blot","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with direct biochemical validation; foundational structural paper replicated by independent cDNA isolation","pmids":["2456210"],"is_preprint":false},{"year":1988,"finding":"CD20 (B1) cDNA was isolated and its amino acid sequence determined, confirming it is a ~33 kDa phosphoprotein with no signal peptide and three major hydrophobic regions consistent with multiple membrane-spanning domains. Two mRNA species (2.8 and 3.4 kb) arise from alternative splicing.","method":"cDNA cloning from tonsillar library, differential hybridization, in vitro translation, limited proteinase digestion peptide mapping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — independent cloning with biochemical validation, peptide mapping confirming identity","pmids":["2448768"],"is_preprint":false},{"year":1988,"finding":"CD20 (B1) is a non-glycosylated phosphoprotein expressed as multiple isoforms (Mr 33,000 and 34,500–36,000). Phosphorylation of B1 is associated with B-cell proliferation: non-proliferating B cells show no 32P incorporation into B1, whereas proliferating/malignant B cells show heavy phosphorylation. Cross-linking B1 on the cell surface with antibody or phorbol ester treatment enhanced phosphorylation. B1(35) contains both phosphoserine and phosphothreonine, while B1(33) contains only phosphoserine, and these isoforms are generated by differential phosphorylation.","method":"32P metabolic labeling, immunoprecipitation, peptide mapping, alkaline phosphatase treatment, PMA stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical characterization with multiple orthogonal methods; mechanistic link between phosphorylation state and proliferation established","pmids":["2454914"],"is_preprint":false},{"year":1988,"finding":"CD20 is a non-glycosylated phosphoprotein: endoglycosidase digestion and tunicamycin labeling confirmed neither the 33 kDa nor the 34,500–36,000 Mr forms are glycosylated. PMA treatment selectively increases phosphorylation and abundance of the 34,500–36,000 Mr form, indicating phosphorylation underlies the molecular weight heterogeneity.","method":"Biosynthetic labeling with [35S]methionine, endoglycosidase digestion, tunicamycin treatment, PMA stimulation, immunoprecipitation","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical experiment with multiple orthogonal methods confirming non-glycosylated status and phosphorylation-driven heterogeneity","pmids":["2467190"],"is_preprint":false},{"year":1993,"finding":"Stable transfection of CD20 cDNA into non-B cell lines (T lymphoblastoid, pre-B lymphoblastoid, K562 erythroleukemia, NIH-3T3 fibroblasts) specifically increased transmembrane Ca2+ conductance as measured by whole-cell patch clamp. Antibody cross-linking of CD20 on lymphoblastoid cells enhanced the same Ca2+ conductance. Biochemical cross-linking suggested CD20 exists as a multimeric oligomer in the membrane, consistent with ion channel formation.","method":"Stable cDNA transfection, whole-cell patch clamp electrophysiology, fluorescence microscopy of cytosolic Ca2+, chemical cross-linking, immunoprecipitation","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in multiple heterologous cell types with direct electrophysiological measurement; strong functional evidence for Ca2+ conductance role","pmids":["7684739"],"is_preprint":false},{"year":1985,"finding":"Anti-B1 (anti-CD20) monoclonal antibodies stimulate resting tonsillar B cells to transition from G0 to G1 phase of the cell cycle, inducing RNA synthesis and growth factor responsiveness but not S-phase entry or mitosis. This activation is inhibited by cyclosporin A (I50 ~50 ng/ml), implicating early activation pathways. Both activatory and inhibitory (of Ig secretion) effects of anti-CD20 depend on distinct epitopes.","method":"B cell proliferation assays, RNA synthesis measurement (3H-uridine), thymidine incorporation, flow cytometry, cyclosporin A inhibition","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean functional experiment with defined cellular phenotype (G0→G1 transition) and pharmacological validation","pmids":["2415587"],"is_preprint":false},{"year":1985,"finding":"Cross-linking of Bp35 (CD20) on the B-cell surface by intact antibody (but not monovalent Fab) is required to trigger B-cell proliferation, indicating that receptor aggregation/multimerization is a mechanistic requirement for CD20-mediated B-cell activation.","method":"B-cell proliferation assays with intact antibody vs. Fab fragments, blocking experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — clean functional dissection using Fab vs. intact antibody; cross-linking requirement clearly established","pmids":["3872456"],"is_preprint":false},{"year":1985,"finding":"The B1 (CD20) molecule is a 32 kDa phosphorylated cell surface protein expressed exclusively from mid pre-B to plasma cell stage. Anti-B1 antibody inhibits B-cell proliferation induced by anti-μ, Staphylococcus aureus Cowan 1, activated T cells, and Epstein-Barr virus, but does not activate B cells itself. Inhibition requires continuous presence of antibody and is maximal when added at culture initiation, suggesting CD20 plays a role in regulating early B-cell activation rather than growth factor-dependent proliferation of pre-activated cells.","method":"Anti-B1 antibody blocking assays, thymidine incorporation, Ig secretion (pokeweed mitogen), co-culture experiments","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple stimulation conditions tested with rigorous controls; functional role in B-cell activation established","pmids":["3925015"],"is_preprint":false},{"year":2002,"finding":"CD20 crosslinking (CD20XL) induces apoptosis in Burkitt lymphoma Ramos cells through a pathway that is distinct from CD95 and BCR-mediated apoptosis: it does not require active caspases (broad-spectrum caspase inhibitor zVAD-fmk blocked caspase processing but not cell death) and cannot be blocked by Bcl-2 overexpression (which blocked cytochrome c release but not CD20XL-induced death), demonstrating a caspase- and mitochondria-independent cell death pathway.","method":"Caspase inhibitor (zVAD-fmk) treatment, Bcl-2 overexpression, annexin V staining, mitochondrial membrane potential assay, cytochrome c release, flow cytometry","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal genetic and pharmacological approaches in same cell system; pathway independence clearly demonstrated","pmids":["12200688"],"is_preprint":false},{"year":2002,"finding":"The ability of anti-CD20 mAbs to activate complement-dependent lysis correlates with their capacity to translocate CD20 into lipid raft (detergent-insoluble) membrane microdomains. mAb B1, which cannot translocate CD20 into rafts, is unable to recruit complement, whereas rituximab and 1F5, which translocate CD20 into rafts, effectively recruit complement. Hyper-cross-linking drove B1 and other mAbs into detergent-insoluble fractions and conferred complement activation ability, directly linking raft residency to complement function.","method":"Membrane fractionation (sucrose gradient), complement lysis assays, hyper-cross-linking with F(ab')2 anti-Ig, panel of anti-B-cell mAbs","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mechanistic link between lipid raft translocation and complement activation established with multiple mAbs and cross-linking rescue experiment","pmids":["12393541"],"is_preprint":false},{"year":2003,"finding":"CD20 is resident in lipid raft (detergent-insoluble) membrane domains. CD40 stimulation of normal human B lymphocytes causes rapid, time- and concentration-dependent internalization of CD20 via translocation into lipid rafts and subsequent uptake into cytoplasmic vesicles. This process is inhibited by cytochalasin B and protein kinase C antagonists. Paradoxically, CD20 down-regulation via CD40 activation enhanced calcium signaling upon subsequent CD20 cross-linking, suggesting CD20 engages downstream signaling pathways that modulate calcium homeostasis rather than functioning as a direct calcium channel.","method":"Confocal fluorescent microscopy, flow cytometry, cytochalasin B inhibition, PKC antagonists, calcium signaling assays, RT-PCR for mRNA stability","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — live imaging and pharmacological dissection with defined signaling readout; multiple orthogonal approaches","pmids":["12938216"],"is_preprint":false},{"year":2003,"finding":"Ectopic expression of CD20 in Chinese hamster ovary cells introduced a novel store-operated cation (SOC) entry pathway permeable to both Ca2+ and Sr2+. Deletion of a cytoplasmic sequence in CD20 essential for raft localization abolished this SOC activity. In B cells, BCR-stimulated Ca2+ influx was significantly reduced by CD20 downregulation (siRNA) and by cholesterol depletion, establishing raft-associated CD20 as a component of the BCR-activated SOC entry pathway.","method":"Ectopic expression in CHO cells, domain deletion mutagenesis, Sr2+/Ca2+ influx assays, siRNA knockdown of CD20, cholesterol depletion (methyl-β-cyclodextrin), B-cell receptor stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution in heterologous cells + mutagenesis + siRNA knockdown in native B cells; strong mechanistic evidence","pmids":["12920111"],"is_preprint":false},{"year":2004,"finding":"In CD20-deficient (CD20−/−) mouse B cells, CD19-induced intracellular calcium responses were significantly reduced compared to wild-type, with a less dramatic effect on IgM-induced responses, establishing a role for CD20 in facilitating transmembrane Ca2+ movement in primary B cells. Immature and mature B-cell IgM expression was ~20–30% lower in CD20−/− mice. B-cell development, tissue localization, signal transduction, proliferation, T cell-dependent antibody responses, and affinity maturation were otherwise normal.","method":"CD20−/− mouse generation and analysis, intracellular calcium flux assays (CD19 and IgM cross-linking), flow cytometry panel","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with defined calcium signaling phenotype; complementary to human CD20 transfection data","pmids":["14688067"],"is_preprint":false},{"year":2005,"finding":"Purified human CD20 expressed in E. coli localizes to the cell membrane and has substantial α-helical secondary structure by circular dichroism spectroscopy. Rituximab binds purified CD20 with nanomolar affinity in a manner abolished by reduction and alkylation, with data consistent with the antibody epitope being within the disulfide-bonded loop formed between cysteine residues C167 and C183. Intact rituximab shows much higher affinity for CD20 on B cells than for isolated CD20, suggesting B cells display CD20 such that avidity effects occur through cross-linking of CD20 monomers, possibly into lipid rafts.","method":"E. coli expression, detergent purification, circular dichroism spectroscopy, surface plasmon resonance (binding kinetics), reduction/alkylation mutagenesis, reoxidation experiments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — purified protein characterization with mutagenesis and direct binding measurements; identifies disulfide-bonded epitope loop","pmids":["16285718"],"is_preprint":false},{"year":2008,"finding":"Type I anti-CD20 mAbs (e.g., rituximab) but not Type II mAbs induce cytosolic Ca2+ flux in B cells, and this requires B-cell antigen receptor (BCR) expression. Type I mAb binding causes direct physical association of CD20 with the BCR (measured by FRET), and phosphorylation of BCR-specific adaptor proteins BLNK and SLP-76. The Ca2+ flux is inhibited by Syk, Src, and PI3K inhibitors but not EGTA, p38, or ERK1/2 inhibitors. BCR-negative Ramos variant cells expressing normal CD20 levels completely fail to flux Ca2+ upon CD20 ligation, demonstrating that CD20-induced Ca2+ signaling is BCR-dependent.","method":"FRET analysis, calcium flux assays, pharmacological inhibitor panel (Syk, Src, PI3K, EGTA, p38, ERK1/2), Western blot for BLNK/SLP-76 phosphorylation, BCR-negative Ramos cell variant, Type I vs. Type II mAb comparison","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — FRET demonstrating direct CD20-BCR association, pharmacological pathway dissection, genetic (BCR-null) validation; multiple orthogonal methods in one study","pmids":["18426802"],"is_preprint":false},{"year":2009,"finding":"A patient with homozygous splice-junction mutation in MS4A1 (CD20 gene) resulting in nonfunctional mRNA and absent CD20 protein showed severely impaired T cell-independent (TI) antibody responses after vaccination with TI antigens, while antigen-independent B-cell development was normal. Consistent results were obtained in CD20-deficient mice for TI antipolysaccharide B-cell responses, establishing CD20 as specifically required for TI humoral immunity.","method":"Human genetic analysis (homozygous MS4A1 splice mutation), patient immunophenotyping, vaccination response assays, CD20−/− mouse TI antigen challenge","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — human loss-of-function (natural mutation) corroborated by mouse knockout; specific phenotype (TI antibody deficiency) with normal B-cell development","pmids":["20038800"],"is_preprint":false},{"year":2011,"finding":"Epitope mapping and X-ray crystallography of the obinutuzumab (GA101, Type II) Fab fragment alone and in complex with a CD20 cyclopeptide revealed that Type I and Type II antibodies recognize overlapping epitopes on CD20's extracellular loop but bind in completely different orientations. GA101's elbow angle is ~30° wider than Type I antibodies, resulting in different spatial arrangements of the two CD20 molecules bound per antibody. Protein tomography and confocal microscopy showed different CD20 membrane complexes and different membrane compartmentalization for Type I vs. Type II antibodies.","method":"X-ray crystallography (Fab alone and Fab-CD20 cyclopeptide complex), epitope fine-mapping, protein tomography, confocal microscopy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with orthogonal tomography and microscopy; mechanistic structural basis for Type I/II distinction established","pmids":["21444918"],"is_preprint":false},{"year":2012,"finding":"TGF-β induces apoptosis of B-cell lymphoma Ramos cells through direct transcriptional repression of MS4A1/CD20 by Smad proteins: chromatin immunoprecipitation (ChIP) showed Smad proteins directly bound the MS4A1 promoter upon TGF-β stimulation, reducing CD20 transcription. CD20 knockdown phenocopied TGF-β-induced apoptosis, while stable CD20 overexpression conferred resistance to TGF-β-induced apoptosis, establishing CD20 as a survival factor downstream of TGF-β/Smad signaling.","method":"Chromatin immunoprecipitation (ChIP) for Smad at MS4A1 promoter, oligonucleotide microarray, siRNA knockdown, stable overexpression, apoptosis assays in vitro and in vivo xenograft","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP directly linking Smad to MS4A1 promoter, functional rescue by overexpression and phenocopy by knockdown; multiple orthogonal methods","pmids":["22665052"],"is_preprint":false},{"year":2017,"finding":"HDAC6 regulates CD20 protein levels post-transcriptionally: HDAC6 inhibition significantly increases CD20 protein in B-cell tumor lines and primary malignant cells without affecting MS4A1 mRNA transcription. HDAC6 inhibition enhances CD20 mRNA translation, shown by increased CD20 mRNA in the polysomal fraction, indicating HDAC6 controls CD20 at the level of mRNA translation. Combined HDAC6 inhibition with anti-CD20 mAbs improved in vitro cytotoxicity and mouse survival.","method":"Pharmacological HDAC6 inhibition, HDAC6 siRNA/shRNA knockdown, flow cytometry for CD20 surface expression, RT-PCR for MS4A1 mRNA, polysome fractionation, in vivo mouse rituximab survival model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — pharmacological and genetic approaches with polysome profiling directly demonstrating translational control; mechanistic novelty confirmed by multiple orthogonal methods","pmids":["28830887"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structure of full-length CD20 in complexes with rituximab (Type I) and ofatumumab (Type I) and obinutuzumab (Type II) at 3.7–4.7 Å resolution revealed that CD20 is a compact double-barrel dimer. Two rituximab Fab fragments each engage a composite epitope with an extensive homotypic Fab:Fab interface. Type II mAb obinutuzumab forms terminal complexes preventing recruitment of additional mAbs and complement components, while Type I complexes act as molecular seeds that increase local mAb concentration for efficient complement activation. Ofatumumab complexes display optimal geometry for complement recruitment.","method":"Cryo-electron microscopy structure determination, binding thermodynamics (ITC/SPR), structural modeling","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures at near-atomic resolution with thermodynamic validation; definitive structural basis for Type I/II mechanisms","pmids":["32792392"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structure of CD20 in complex with rituximab revealed CD20 as a compact double-barrel dimer bound by two RTX Fab fragments, each engaging a composite epitope with an extensive homotypic Fab:Fab interface. The structure suggests RTX cross-links CD20 into circular assemblies on the B-cell surface and provides a structural model for complement recruitment, explaining the mechanism of complement-dependent cytotoxicity.","method":"Cryo-EM structure determination","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — atomic-resolution cryo-EM structure; first structure of CD20 protein itself","pmids":["32079680"],"is_preprint":false},{"year":1996,"finding":"Flow cytometric energy transfer (FRET) analysis demonstrated that CD20 at the B-cell surface is in close proximity (within 2–10 nm) to MHC class I, MHC class II (DR, DQ), and tetraspan molecules CD53, CD81, and CD82 in a single supramolecular complex, suggesting CD20 participates in multicomponent membrane assemblies that may be involved in signaling and antigen presentation.","method":"Flow cytometric FRET with fluorescently labeled antibodies","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 — FRET proximity data is supportive but not biochemical co-IP; single lab, no functional follow-up in this study","pmids":["8816400"],"is_preprint":false},{"year":2003,"finding":"The FMC7 monoclonal antibody specifically recognizes CD20 expressed in multiple cell lines, and this reactivity is abolished by mutations in the extracellular domain of CD20. The FMC7 epitope on CD20 is exceptionally sensitive to membrane cholesterol: cholesterol depletion profoundly reduces FMC7 epitope expression, while cholesterol enrichment enhances it, indicating that a cholesterol-dependent conformational state of CD20 exists in the plasma membrane.","method":"Ectopic CD20 expression in hematopoietic and non-hematopoietic cell lines, extracellular domain mutation analysis, cholesterol depletion (methyl-β-cyclodextrin) and enrichment, flow cytometry","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis and cholesterol manipulation with clear functional readout; single lab but multiple cell systems","pmids":["12835728"],"is_preprint":false},{"year":2023,"finding":"MS4A1/CD20 mRNA is produced as multiple isoforms with distinct 5' UTRs (V1–V4). V1, the most abundant isoform, contains upstream open reading frames (uORFs) and a stem-loop structure that cooperatively inhibit polysome recruitment, rendering V1 translation-deficient. V3 is the translation-competent isoform and correlates with CD20 protein levels in DLBCL. Reconstitution of CD20-knockout cells with V3 mRNA restored CD20 surface expression; V1 reconstitution produced undetectable CD20 protein. Splice-switching morpholino oligomers redirecting splicing from V1 to V3 enhanced CD20 expression and rituximab-mediated cytotoxicity. V3→V1 splicing shift was identified in post-mosunetuzumab relapsed follicular lymphoma samples.","method":"RNA sequencing, ribosome profiling/polysome analysis, morpholino splice-switching, CD20-knockout cell reconstitution with V1 or V3 mRNA, flow cytometry, cytotoxicity assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution experiments (V1 vs. V3 in KO cells) + polysome profiling + clinical splice-shift validation; multiple orthogonal methods; mechanistically resolves post-transcriptional regulation of CD20","pmids":["37683180"],"is_preprint":false},{"year":2025,"finding":"Using TDI-DNA-PAINT combined with lattice light-sheet microscopy on live B cells, endogenous CD20 was found to be abundantly expressed on microvilli. Therapeutic mAbs (rituximab, ofatumumab, obinutuzumab) bind CD20 on microvilli in an antibody concentration-dependent manner, leading to B-cell polarization and stabilization of microvilli protrusions. Different mAbs produced distinct oligomeric states of CD20 on the cell surface.","method":"TDI-DNA-PAINT super-resolution microscopy, lattice light-sheet (LLS) microscopy, live B-cell imaging","journal":"Science","confidence":"Medium","confidence_rationale":"Tier 2 — novel super-resolution imaging with functional consequence (polarization); single lab, methodology is novel but functional validation is limited","pmids":["39787234"],"is_preprint":false}],"current_model":"CD20 (MS4A1) is a non-glycosylated, phosphorylated tetraspan membrane protein that exists as a double-barrel dimer in lipid raft microdomains of B-cell membranes; it regulates transmembrane Ca2+ conductance and store-operated Ca2+ entry by associating with and activating the B-cell antigen receptor (BCR) signaling cascade (requiring Syk, Src, and PI3K), promotes B-cell transition from G0 to G1, is required for T cell-independent antibody responses, undergoes differential phosphorylation that correlates with proliferative state, has its protein levels post-transcriptionally regulated by HDAC6-dependent translational control and by alternative 5'-UTR splicing (V1 isoform contains inhibitory uORFs/stem-loop; V3 is translation-competent), and is subject to direct transcriptional repression by TGF-β/Smad signaling; its translocation into lipid rafts upon Type I mAb ligation determines complement-dependent cytotoxicity, while Type II mAbs bind CD20 in a distinct orientation forming terminal complexes that preclude complement recruitment."},"narrative":{"teleology":[{"year":1985,"claim":"Establishing that CD20 has a direct role in B-cell activation: antibody cross-linking of CD20 drives resting B cells from G0 to G1, while monovalent Fab fragments are inactive, demonstrating that receptor aggregation is the mechanistic trigger for activation signaling.","evidence":"B-cell proliferation assays with intact antibody versus Fab fragments, cyclosporin A inhibition, and multi-stimulus blocking experiments on tonsillar B cells","pmids":["2415587","3872456","3925015"],"confidence":"High","gaps":["Downstream signaling pathway from CD20 aggregation was unknown","Whether CD20 functions as an intrinsic signaling receptor or accessory molecule was unresolved"]},{"year":1988,"claim":"Molecular cloning and biochemical characterization revealed CD20 as a non-glycosylated phosphoprotein with multiple transmembrane domains and no homology to known proteins, with differential phosphorylation (serine and threonine) correlating with B-cell proliferative state.","evidence":"cDNA cloning from two independent groups, in vitro translation, 32P metabolic labeling, endoglycosidase digestion, tunicamycin treatment, PMA stimulation","pmids":["2456210","2448768","2454914","2467190"],"confidence":"High","gaps":["Identity of kinases phosphorylating CD20 was unknown","Functional consequence of individual phosphorylation sites was not mapped","Membrane topology was inferred from hydropathy, not experimentally determined"]},{"year":1993,"claim":"Reconstitution of CD20 in multiple non-B cell lines demonstrated that CD20 directly increases transmembrane Ca²⁺ conductance, and chemical cross-linking revealed CD20 exists as a multimer consistent with ion channel or channel-regulatory function.","evidence":"Stable cDNA transfection into T cells, pre-B cells, K562, and NIH-3T3; whole-cell patch clamp electrophysiology; chemical cross-linking and immunoprecipitation","pmids":["7684739"],"confidence":"High","gaps":["Whether CD20 itself forms a pore or activates an endogenous channel was unresolved","Ion selectivity and single-channel properties were not characterized"]},{"year":1996,"claim":"FRET analysis revealed CD20 resides within 2–10 nm of MHC class I, MHC class II, and tetraspanins CD53/CD81/CD82, suggesting it participates in supramolecular membrane signaling complexes.","evidence":"Flow cytometric energy transfer with fluorescently labeled antibodies on B cells","pmids":["8816400"],"confidence":"Medium","gaps":["Proximity data did not confirm direct physical interaction","Functional significance of CD20–tetraspanin association was not tested","No reciprocal co-immunoprecipitation was performed"]},{"year":2002,"claim":"CD20 cross-linking was shown to induce a caspase- and Bcl-2-independent apoptotic pathway, and separately, the ability of anti-CD20 mAbs to activate complement was mechanistically linked to their capacity to translocate CD20 into lipid raft microdomains.","evidence":"Caspase inhibitor and Bcl-2 overexpression experiments in Ramos cells; membrane fractionation and complement lysis assays with Type I and Type II mAb panels; hyper-cross-linking rescue","pmids":["12200688","12393541"],"confidence":"High","gaps":["Identity of the caspase-independent death effector was unknown","Whether raft residency was necessary for all CD20 effector functions beyond complement was untested"]},{"year":2003,"claim":"CD20 was established as a component of the BCR-activated store-operated calcium (SOC) entry pathway: ectopic expression in CHO cells introduced SOC activity dependent on a raft-targeting cytoplasmic domain, and siRNA knockdown in B cells reduced BCR-stimulated Ca²⁺ influx. Cholesterol-dependent conformational states of CD20 were also demonstrated.","evidence":"Reconstitution in CHO cells with deletion mutagenesis, siRNA knockdown in B cells, cholesterol depletion/enrichment, Ca²⁺/Sr²⁺ influx assays, CD40-stimulated internalization microscopy","pmids":["12920111","12835728","12938216"],"confidence":"High","gaps":["Molecular identity of the SOC channel activated by CD20 was not determined","Whether CD20 is the pore-forming subunit or an accessory/regulatory subunit remained open"]},{"year":2004,"claim":"CD20-knockout mice confirmed a physiological role for CD20 in transmembrane Ca²⁺ signaling—particularly CD19-induced responses—while revealing that B-cell development and T cell-dependent immunity are largely CD20-independent.","evidence":"CD20⁻/⁻ mouse generation, intracellular calcium flux upon CD19 and IgM cross-linking, flow cytometry phenotyping","pmids":["14688067"],"confidence":"High","gaps":["T cell-independent responses in CD20⁻/⁻ mice were not tested in this study","Mechanism linking CD20 to CD19-specific calcium signaling was not identified"]},{"year":2005,"claim":"Structural characterization of purified CD20 revealed substantial α-helical content and showed that the rituximab epitope requires a disulfide bond between C167 and C183 in the extracellular loop, with avidity effects on intact B cells suggesting CD20 multimerization on the cell surface.","evidence":"E. coli expression and purification, circular dichroism spectroscopy, surface plasmon resonance, reduction/alkylation mutagenesis","pmids":["16285718"],"confidence":"High","gaps":["No high-resolution structure was yet available","Stoichiometry of native CD20 complexes on B cells was unknown"]},{"year":2008,"claim":"The mechanism of CD20-induced Ca²⁺ signaling was resolved: Type I mAbs cause direct physical association of CD20 with the BCR (by FRET), activate BLNK/SLP-76 phosphorylation, and require Syk, Src, and PI3K—BCR-negative cells expressing normal CD20 completely fail to signal, demonstrating CD20 Ca²⁺ flux is BCR-dependent rather than intrinsic channel activity.","evidence":"FRET for CD20–BCR proximity, pharmacological kinase inhibitor panel, BCR-negative Ramos variant, Western blot for adaptor phosphorylation","pmids":["18426802"],"confidence":"High","gaps":["How CD20 physically engages the BCR complex was not structurally resolved","Whether CD20 directly contacts BCR or requires an intermediary was unknown"]},{"year":2009,"claim":"A human loss-of-function mutation in MS4A1 established CD20 as specifically required for T cell-independent antibody responses, the first Mendelian phenotype linked to CD20 deficiency.","evidence":"Homozygous splice-junction mutation in a patient, vaccination response assays for TI antigens, corroboration in CD20⁻/⁻ mice","pmids":["20038800"],"confidence":"High","gaps":["Mechanism by which CD20 specifically enables TI responses was not elucidated","Whether the phenotype extends to other TI antigen classes was not fully tested"]},{"year":2011,"claim":"X-ray crystallography of the obinutuzumab Fab–CD20 peptide complex revealed that Type I and Type II mAbs bind overlapping epitopes in completely different orientations, explaining their divergent capacities for complement activation and raft redistribution.","evidence":"X-ray crystallography of Fab alone and Fab–cyclopeptide complex, protein tomography, confocal microscopy","pmids":["21444918"],"confidence":"High","gaps":["Structure was of Fab with a cyclopeptide, not full-length membrane-embedded CD20","Orientation differences did not explain direct homotypic killing by Type II mAbs"]},{"year":2012,"claim":"TGF-β/Smad signaling was shown to directly repress MS4A1 transcription by Smad binding at the promoter, and CD20 knockdown phenocopied TGF-β-induced apoptosis while overexpression conferred resistance, establishing CD20 as a Smad-regulated survival factor.","evidence":"ChIP for Smad at MS4A1 promoter, siRNA knockdown, stable overexpression, apoptosis assays in vitro and in vivo xenograft","pmids":["22665052"],"confidence":"High","gaps":["Whether Smad-mediated CD20 repression operates in normal B cells beyond lymphoma was untested","Whether CD20's survival function is calcium-dependent was not determined"]},{"year":2017,"claim":"HDAC6 was identified as a post-transcriptional regulator of CD20: HDAC6 inhibition increases CD20 protein without affecting mRNA levels, by enhancing MS4A1 mRNA loading onto polysomes—revealing a translational control mechanism with therapeutic implications for anti-CD20 therapy.","evidence":"Pharmacological and genetic HDAC6 inhibition, polysome fractionation, flow cytometry, in vivo rituximab survival model","pmids":["28830887"],"confidence":"High","gaps":["The HDAC6 substrate mediating translational control of CD20 mRNA was not identified","Whether HDAC6 acts via the 5′-UTR splicing mechanism was unknown"]},{"year":2020,"claim":"Cryo-EM structures of full-length CD20 in complex with rituximab, ofatumumab, and obinutuzumab at 3.7–4.7 Å resolution defined CD20 as a compact double-barrel dimer and revealed that Type I mAbs cross-link dimers into supramolecular assemblies that seed complement, while Type II mAbs form terminal complexes that preclude complement recruitment.","evidence":"Cryo-EM structure determination with ITC/SPR binding thermodynamics","pmids":["32079680","32792392"],"confidence":"High","gaps":["No structure of CD20 in its native lipid environment or without mAb was obtained","Whether oligomeric assemblies form on live cell membranes at physiological mAb concentrations was not proven"]},{"year":2023,"claim":"Alternative 5′-UTR splicing of MS4A1 mRNA was revealed as a major determinant of CD20 protein expression: the abundant V1 isoform contains inhibitory uORFs and a stem-loop that block translation, while V3 is translation-competent, and V1-to-V3 splice-switching enhanced CD20 surface expression and rituximab efficacy.","evidence":"RNA sequencing, ribosome profiling, morpholino splice-switching, CD20-KO reconstitution with V1 or V3, clinical relapse sample analysis","pmids":["37683180"],"confidence":"High","gaps":["Trans-acting factors controlling V1/V3 splice choice were not identified","Relationship between HDAC6-mediated translational control and 5′-UTR isoform usage was not tested"]},{"year":2025,"claim":"Super-resolution imaging localized endogenous CD20 to B-cell microvilli and showed that therapeutic mAbs induce distinct oligomeric states and B-cell polarization, adding a spatial dimension to understanding of mAb mechanism of action.","evidence":"TDI-DNA-PAINT and lattice light-sheet microscopy on live B cells","pmids":["39787234"],"confidence":"Medium","gaps":["Functional consequence of microvillar CD20 localization for signaling or cytotoxicity was not established","Whether microvillar enrichment is constitutive or activation-dependent was not resolved","Single-lab methodology awaits independent replication"]},{"year":null,"claim":"Key unresolved questions include the molecular identity of the ion conductance pathway regulated by CD20 (intrinsic pore versus activation of a distinct channel), the HDAC6 substrate controlling CD20 mRNA translation, the trans-acting splicing factors governing V1/V3 5′-UTR isoform selection, and the structural basis for CD20's selective requirement in T cell-independent humoral immunity.","evidence":"","pmids":[],"confidence":"High","gaps":["No structure of apo CD20 dimer without antibody bound","No reconstitution of CD20 ion conductance with defined channel identity","Mechanism linking CD20 to TI-specific B-cell signaling is uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[4,11,12]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[14,11]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,9,10,13,19,20,24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,7,14,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,11,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[8,17]}],"complexes":["CD20 double-barrel homodimer"],"partners":["BCR (IGM)","CD19","CD53","CD81","CD82","BLNK","SLP-76"],"other_free_text":[]},"mechanistic_narrative":"CD20 (MS4A1) is a non-glycosylated, differentially phosphorylated tetraspan membrane protein that functions as a compact double-barrel dimer in lipid raft microdomains of B lymphocytes, where it regulates store-operated calcium entry and couples to B-cell antigen receptor (BCR) signaling through Syk, Src, and PI3K kinases to promote B-cell activation from G0 to G1 [PMID:7684739, PMID:12920111, PMID:18426802, PMID:2415587]. Homozygous loss-of-function mutations in MS4A1 cause selective deficiency of T cell-independent antibody responses while leaving B-cell development intact [PMID:20038800]. Cryo-EM structures reveal that Type I anti-CD20 monoclonal antibodies (rituximab, ofatumumab) cross-link CD20 dimers into assemblies that seed complement recruitment, whereas Type II antibodies (obinutuzumab) form terminal complexes that preclude complement activation, explaining their divergent cytotoxic mechanisms [PMID:32079680, PMID:32792392]. CD20 protein levels are controlled post-transcriptionally by HDAC6-dependent translational regulation and by alternative 5′-UTR splicing—the V1 isoform contains inhibitory uORFs and a stem-loop that suppress translation, while V3 is the translation-competent form—and transcriptionally by TGF-β/Smad-mediated repression of the MS4A1 promoter [PMID:28830887, PMID:37683180, PMID:22665052]."},"prefetch_data":{"uniprot":{"accession":"P11836","full_name":"B-lymphocyte antigen CD20","aliases":["B-lymphocyte surface antigen B1","Bp35","Leukocyte surface antigen Leu-16","Membrane-spanning 4-domains subfamily A member 1"],"length_aa":297,"mass_kda":33.1,"function":"B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:12920111, PubMed:3925015, PubMed:7684739). Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:12920111, PubMed:18474602, PubMed:7684739)","subcellular_location":"Cell membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P11836/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MS4A1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MS4A1","total_profiled":1310},"omim":[{"mim_id":"613495","title":"IMMUNODEFICIENCY, COMMON VARIABLE, 5; CVID5","url":"https://www.omim.org/entry/613495"},{"mim_id":"606550","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 12; MS4A12","url":"https://www.omim.org/entry/606550"},{"mim_id":"606549","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 8B; MS4A8B","url":"https://www.omim.org/entry/606549"},{"mim_id":"606548","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6A; MS4A6A","url":"https://www.omim.org/entry/606548"},{"mim_id":"606547","title":"MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 4A; MS4A4A","url":"https://www.omim.org/entry/606547"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":631.0}],"url":"https://www.proteinatlas.org/search/MS4A1"},"hgnc":{"alias_symbol":["B1","Bp35","FMC7"],"prev_symbol":["CD20"]},"alphafold":{"accession":"P11836","domains":[{"cath_id":"-","chopping":"40-243","consensus_level":"high","plddt":82.5539,"start":40,"end":243}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11836","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11836-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11836-F1-predicted_aligned_error_v6.png","plddt_mean":70.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MS4A1","jax_strain_url":"https://www.jax.org/strain/search?query=MS4A1"},"sequence":{"accession":"P11836","fasta_url":"https://rest.uniprot.org/uniprotkb/P11836.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11836/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11836"}},"corpus_meta":[{"pmid":"7687326","id":"PMC_7687326","title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.","date":"1993","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7687326","citation_count":564,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7524522","id":"PMC_7524522","title":"CD20: a regulator of cell-cycle progression of B lymphocytes.","date":"1994","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/7524522","citation_count":497,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3487090","id":"PMC_3487090","title":"Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3487090","citation_count":496,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17768100","id":"PMC_17768100","title":"Mechanisms of killing by anti-CD20 monoclonal antibodies.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17768100","citation_count":415,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22053081","id":"PMC_22053081","title":"Upregulation of Cyclin B1 by miRNA and its implications in cancer.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22053081","citation_count":251,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15564720","id":"PMC_15564720","title":"The biology of CD20 and its potential as a target for mAb therapy.","date":"2005","source":"Current directions in autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/15564720","citation_count":238,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9675258","id":"PMC_9675258","title":"Activation and detoxication of aflatoxin B1.","date":"1998","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/9675258","citation_count":236,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3872456","id":"PMC_3872456","title":"Role of the Bp35 cell surface polypeptide in human B-cell activation.","date":"1985","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3872456","citation_count":211,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29716920","id":"PMC_29716920","title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29716920","citation_count":200,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14688067","id":"PMC_14688067","title":"Mouse CD20 expression and function.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14688067","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2415587","id":"PMC_2415587","title":"The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.","date":"1985","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2415587","citation_count":171,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32079680","id":"PMC_32079680","title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32079680","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28695471","id":"PMC_28695471","title":"Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.","date":"2017","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28695471","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29046676","id":"PMC_29046676","title":"Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29046676","citation_count":136,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18585457","id":"PMC_18585457","title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.","date":"2008","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18585457","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18220605","id":"PMC_18220605","title":"The potential role of thiamine (vitamin B1) in diabetic complications.","date":"2005","source":"Current diabetes reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18220605","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37389565","id":"PMC_37389565","title":"The importance of thiamine (vitamin B1) in humans.","date":"2023","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/37389565","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16169773","id":"PMC_16169773","title":"The therapeutic potential of anti-CD20 \"what do B-cells do?\".","date":"2005","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/16169773","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32792392","id":"PMC_32792392","title":"Binding mechanisms of therapeutic antibodies to human CD20.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32792392","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21555250","id":"PMC_21555250","title":"Treatment of multiple sclerosis with anti-CD20 antibodies.","date":"2011","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/21555250","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6788112","id":"PMC_6788112","title":"Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.","date":"1981","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/6788112","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9634476","id":"PMC_9634476","title":"Mice carrying a CD20 gene disruption.","date":"1998","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9634476","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11564080","id":"PMC_11564080","title":"Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.","date":"2001","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/11564080","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2961848","id":"PMC_2961848","title":"Mutation in GM2-gangliosidosis B1 variant.","date":"1988","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2961848","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3492530","id":"PMC_3492530","title":"Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors.","date":"1987","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3492530","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2454914","id":"PMC_2454914","title":"Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2454914","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12200688","id":"PMC_12200688","title":"CD20-induced B cell death can bypass mitochondria and caspase activation.","date":"2002","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12200688","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11043779","id":"PMC_11043779","title":"Generation, expansion, migration and activation of mouse B1 cells.","date":"2000","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11043779","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30089638","id":"PMC_30089638","title":"Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.","date":"2018","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30089638","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16285718","id":"PMC_16285718","title":"Isolation and characterization of the B-cell marker CD20.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16285718","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33092190","id":"PMC_33092190","title":"Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.","date":"2020","source":"Brain sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33092190","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9738982","id":"PMC_9738982","title":"Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.","date":"1998","source":"Japanese journal of cancer research : Gann","url":"https://pubmed.ncbi.nlm.nih.gov/9738982","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22654880","id":"PMC_22654880","title":"Human b1 cell frequency: isolation and analysis of human b1 cells.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22654880","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25535332","id":"PMC_25535332","title":"Role of lamin b1 in chromatin instability.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25535332","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30594067","id":"PMC_30594067","title":"DNA damage checkpoint response to aflatoxin B1.","date":"2018","source":"Environmental toxicology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30594067","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21486448","id":"PMC_21486448","title":"The predictive significance of CD20 expression in B-cell lymphomas.","date":"2011","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21486448","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19276251","id":"PMC_19276251","title":"Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19276251","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25733518","id":"PMC_25733518","title":"Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.","date":"2015","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25733518","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27752134","id":"PMC_27752134","title":"The B1 Protein Guides the Biosynthesis of a Lasso Peptide.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27752134","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29468712","id":"PMC_29468712","title":"New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.","date":"2018","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/29468712","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30525563","id":"PMC_30525563","title":"Total Enzyme Syntheses of Napyradiomycins A1 and B1.","date":"2018","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/30525563","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2111122","id":"PMC_2111122","title":"Interconversion of aflatoxin B1 and aflatoxicol by several fungi.","date":"1990","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/2111122","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15047755","id":"PMC_15047755","title":"CD20 positive T cell lymphoma: is it a real entity?","date":"2004","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15047755","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11958538","id":"PMC_11958538","title":"DNA damage in astrocytes exposed to fumonisin B1.","date":"2002","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/11958538","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8832074","id":"PMC_8832074","title":"B1 bradykinin receptors and sensory neurones.","date":"1996","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8832074","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2467190","id":"PMC_2467190","title":"Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes.","date":"1988","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2467190","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12938216","id":"PMC_12938216","title":"Down-regulation of CD20 on B cells upon CD40 activation.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12938216","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37286611","id":"PMC_37286611","title":"Class B1 GPCR activation by an intracellular agonist.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37286611","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30639700","id":"PMC_30639700","title":"CD3+CD20+ T cells and their roles in human diseases.","date":"2019","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30639700","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11195464","id":"PMC_11195464","title":"Mechanisms of aflatoxin B1 lung tumorigenesis.","date":"2000","source":"Experimental lung research","url":"https://pubmed.ncbi.nlm.nih.gov/11195464","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28830887","id":"PMC_28830887","title":"HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28830887","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32148929","id":"PMC_32148929","title":"Thiamine (vitamin B1) in septic shock: a targeted therapy.","date":"2020","source":"Journal of thoracic disease","url":"https://pubmed.ncbi.nlm.nih.gov/32148929","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33352466","id":"PMC_33352466","title":"MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment.","date":"2020","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33352466","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18187413","id":"PMC_18187413","title":"Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18187413","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17303402","id":"PMC_17303402","title":"Unraveling B-1 progenitors.","date":"2007","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17303402","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29680634","id":"PMC_29680634","title":"The Dual Face of Cyclin B1.","date":"2018","source":"Trends in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/29680634","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20448019","id":"PMC_20448019","title":"Blockade of the kinin B1 receptor ameloriates glomerulonephritis.","date":"2010","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/20448019","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7523045","id":"PMC_7523045","title":"Low level CD20 expression on T cell malignancies.","date":"1994","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/7523045","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12034754","id":"PMC_12034754","title":"Initial activation of cyclin-B1-cdc2 kinase requires phosphorylation of cyclin B1.","date":"2002","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/12034754","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26763128","id":"PMC_26763128","title":"Response of the hepatic transcriptome to aflatoxin B1 in ducklings.","date":"2016","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/26763128","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27354469","id":"PMC_27354469","title":"CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27354469","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37683180","id":"PMC_37683180","title":"Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37683180","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20404351","id":"PMC_20404351","title":"Scavenger receptor-B1 and luteal function in mice.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/20404351","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14608903","id":"PMC_14608903","title":"Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.","date":"2003","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14608903","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35951029","id":"PMC_35951029","title":"CD20+ T cells: an emerging T cell subset in human pathology.","date":"2022","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/35951029","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12489793","id":"PMC_12489793","title":"Activation of bradykinin B1 receptor by ACE inhibitors.","date":"2002","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12489793","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15195108","id":"PMC_15195108","title":"Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray.","date":"2004","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15195108","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20015472","id":"PMC_20015472","title":"Metabolic intervention of aflatoxin B1 toxicity by curcumin.","date":"2009","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20015472","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38253219","id":"PMC_38253219","title":"scRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20+ B cells.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38253219","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25086174","id":"PMC_25086174","title":"Translational medicine in action: anti-CD20 therapy in lymphoma.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25086174","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22665052","id":"PMC_22665052","title":"TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22665052","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8135183","id":"PMC_8135183","title":"Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody.","date":"1994","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8135183","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17010619","id":"PMC_17010619","title":"An RNA polymerase inhibitor, cyclothiazomycin B1, and its isomer.","date":"2006","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17010619","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19028417","id":"PMC_19028417","title":"Aurora-A interacts with Cyclin B1 and enhances its stability.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19028417","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6427340","id":"PMC_6427340","title":"The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression.","date":"1984","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/6427340","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34263696","id":"PMC_34263696","title":"Glofitamab CD20-TCB bispecific antibody.","date":"2021","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/34263696","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36006180","id":"PMC_36006180","title":"Impact of Mycotoxin Contaminations on Aquatic Organisms: Toxic Effect of Aflatoxin B1 and Fumonisin B1 Mixture.","date":"2022","source":"Toxins","url":"https://pubmed.ncbi.nlm.nih.gov/36006180","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6138886","id":"PMC_6138886","title":"The neurotoxicity of aflatoxin B1 in the rat.","date":"1983","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/6138886","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32972448","id":"PMC_32972448","title":"The immunomodulatory effect of cathelicidin-B1 on chicken macrophages.","date":"2020","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/32972448","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27242666","id":"PMC_27242666","title":"ACTH Regulation of Adrenal SR-B1.","date":"2016","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27242666","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35107765","id":"PMC_35107765","title":"SR-B1's Next Top Model: Structural Perspectives on the Functions of the HDL Receptor.","date":"2022","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/35107765","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1376065","id":"PMC_1376065","title":"CD20 and CD5 expression in B-chronic lymphocytic leukemia.","date":"1992","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/1376065","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34516013","id":"PMC_34516013","title":"Proinflammatory CD20+ T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.","date":"2021","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34516013","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1602214","id":"PMC_1602214","title":"Cytokines and Ly-1 (B1) B cells.","date":"1992","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1602214","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29377068","id":"PMC_29377068","title":"Dissection of a circulating CD3+ CD20+ T cell subpopulation in patients with psoriasis.","date":"2018","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29377068","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24244415","id":"PMC_24244415","title":"CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24244415","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24696233","id":"PMC_24696233","title":"CD20+ B cell depletion alters T cell homing.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24696233","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10712945","id":"PMC_10712945","title":"B-1 cells: orthodox or conformist?","date":"2000","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10712945","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31721035","id":"PMC_31721035","title":"Ontogeny of human B1 cells.","date":"2019","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/31721035","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24722282","id":"PMC_24722282","title":"Liver kinase B1 regulates the centrosome via PLK1.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24722282","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26880268","id":"PMC_26880268","title":"CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26880268","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18713565","id":"PMC_18713565","title":"Spotlight on anti-CD20.","date":"2008","source":"International MS journal","url":"https://pubmed.ncbi.nlm.nih.gov/18713565","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37369602","id":"PMC_37369602","title":"Intrathecal CD8+CD20+ T Cells in Primary Progressive Multiple Sclerosis.","date":"2023","source":"Neurology(R) neuroimmunology & neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/37369602","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32744145","id":"PMC_32744145","title":"Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.","date":"2020","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/32744145","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20083213","id":"PMC_20083213","title":"Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.","date":"2010","source":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/20083213","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12835728","id":"PMC_12835728","title":"A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/12835728","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27854160","id":"PMC_27854160","title":"Lamin B1 mediated demyelination: Linking Lamins, Lipids and Leukodystrophies.","date":"2016","source":"Nucleus (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/27854160","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24670986","id":"PMC_24670986","title":"Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.","date":"2014","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/24670986","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3257502","id":"PMC_3257502","title":"Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3257502","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39787234","id":"PMC_39787234","title":"Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy.","date":"2025","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39787234","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3117132","id":"PMC_3117132","title":"Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3117132","citation_count":458,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19641607","id":"PMC_19641607","title":"Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19641607","citation_count":361,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7920628","id":"PMC_7920628","title":"Association between atopy and variants of the beta subunit of the high-affinity immunoglobulin E receptor.","date":"1994","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7920628","citation_count":327,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12393541","id":"PMC_12393541","title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393541","citation_count":301,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20038800","id":"PMC_20038800","title":"CD20 deficiency in humans results in impaired T cell-independent antibody responses.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20038800","citation_count":276,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26858360","id":"PMC_26858360","title":"Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes.","date":"2016","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26858360","citation_count":271,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7684739","id":"PMC_7684739","title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7684739","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2456210","id":"PMC_2456210","title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.","date":"1988","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2456210","citation_count":267,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20641064","id":"PMC_20641064","title":"B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20641064","citation_count":254,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3871452","id":"PMC_3871452","title":"Human B cell development. II. Subpopulations in the human fetus.","date":"1985","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3871452","citation_count":253,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24928997","id":"PMC_24928997","title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24928997","citation_count":226,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20458337","id":"PMC_20458337","title":"MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis.","date":"2010","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20458337","citation_count":221,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19246561","id":"PMC_19246561","title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19246561","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2448768","id":"PMC_2448768","title":"Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2448768","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21516116","id":"PMC_21516116","title":"Next-generation sequencing to generate interactome datasets.","date":"2011","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/21516116","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3925015","id":"PMC_3925015","title":"The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.","date":"1985","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3925015","citation_count":197,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21348573","id":"PMC_21348573","title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.","date":"2011","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/21348573","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21444918","id":"PMC_21444918","title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21444918","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8816400","id":"PMC_8816400","title":"Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8816400","citation_count":177,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20350657","id":"PMC_20350657","title":"CD20 as a target for therapeutic type I and II monoclonal antibodies.","date":"2010","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/20350657","citation_count":170,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12920111","id":"PMC_12920111","title":"Store-operated cation entry mediated by CD20 in membrane rafts.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12920111","citation_count":135,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16095505","id":"PMC_16095505","title":"Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.","date":"2005","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/16095505","citation_count":121,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18426802","id":"PMC_18426802","title":"Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18426802","citation_count":119,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43841,"output_tokens":4735,"usd":0.101274},"stage2":{"model":"claude-opus-4-6","input_tokens":8270,"output_tokens":3187,"usd":0.181537},"total_usd":0.664859,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":56654,"output_tokens":7444,"usd":0.140811},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11160,"output_tokens":4201,"usd":0.241237}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"CD20 (Bp35) cross-linking by monoclonal antibody requires bivalent engagement (Fab fragments block but do not activate), indicating that receptor aggregation/cross-linking is required to transmit a B-cell activation signal.\",\n      \"method\": \"Monoclonal antibody stimulation assays with whole antibody vs. Fab fragments on tonsillar B cells; proliferation and RNA synthesis readouts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional assays with Fab blocking and whole-Ab activation, replicated across multiple studies\",\n      \"pmids\": [\"3872456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"CD20 (Bp35) engagement activates resting B cells to transition from G0 to G1 phase of the cell cycle, inducing RNA synthesis and cell enlargement; cyclosporin A inhibits this at early stage.\",\n      \"method\": \"Monoclonal antibody stimulation (1F5 anti-CD20) of tonsillar B cells; thymidine incorporation, RNA synthesis, cyclosporin A inhibition assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined cellular phenotype (G0→G1 transition) with pharmacological inhibitor confirming early-stage mechanism, replicated across labs\",\n      \"pmids\": [\"2415587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"CD20 (Bp35) and CD40 (Bp50) mediate distinct B-cell activation signals: anti-CD20 activates resting B cells (G0→G1), while anti-CD40 acts as a co-stimulatory progression signal for already-activated B cells, and together they synergize to drive strong proliferation of resting B cells.\",\n      \"method\": \"Monoclonal antibody stimulation assays with anti-Bp35 and anti-Bp50 alone and in combination on purified tonsillar B cells; proliferation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis-like functional dissection with defined cellular phenotypes, replicated across conditions\",\n      \"pmids\": [\"3487090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"CD20 (B1) is a non-glycosylated phosphoprotein existing in multiple isoforms (Mr 33,000 and 34,500–36,000). Phosphorylation is associated with B-cell proliferation; cross-linking CD20 on the cell surface or treatment with phorbol esters (PKC activators) enhances CD20 phosphorylation, demonstrating that antibody binding to CD20 generates a transmembrane signal linked to PKC activation.\",\n      \"method\": \"32P metabolic labeling, peptide mapping, alkaline phosphatase treatment, phorbol ester and DAG analog stimulation of B-cell lines; immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical in vitro assays with multiple orthogonal methods (phosphorylation, peptide mapping, pharmacological stimulation)\",\n      \"pmids\": [\"2454914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"CD20 exists in heterogeneous non-glycosylated forms; endoglycosidase and tunicamycin studies confirm absence of glycosylation; PMA treatment increases phosphorylation of the Mr 34,500–36,000 form specifically, indicating differential phosphorylation regulates isoform expression.\",\n      \"method\": \"Endoglycosidase digestion, tunicamycin metabolic labeling, PMA stimulation, immunoprecipitation from surface-iodinated B-cell lines\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical methods in a single study\",\n      \"pmids\": [\"2467190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD20-deficient mice (CD20−/−) display reduced CD19-induced intracellular calcium responses in primary B cells, with a less dramatic effect on IgM-induced responses, demonstrating CD20 plays a role in transmembrane Ca2+ movement downstream of CD19 signaling.\",\n      \"method\": \"CD20 knockout mouse model; intracellular calcium flux measurements in primary B cells stimulated via CD19 or IgM\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype (Ca2+ flux), orthogonally validated in mouse primary cells\",\n      \"pmids\": [\"9634476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mouse CD20−/− primary B cells show significantly reduced CD19-induced intracellular calcium responses, complementing data from human CD20 cDNA-transfected cell lines, confirming CD20 facilitates transmembrane Ca2+ movement in primary B cells.\",\n      \"method\": \"CD20-deficient mouse model; calcium flux assays in primary B cells; comparison with wild-type littermates\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined calcium flux phenotype, cross-species validation of mechanism\",\n      \"pmids\": [\"14688067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD40 activation induces rapid CD20 down-regulation in human B lymphocytes via translocation of CD20 into lipid rafts and internalization into cytoplasmic vesicles; this process is inhibited by cytochalasin B and PKC antagonists. Paradoxically, internalized CD20 shows enhanced calcium signaling upon cross-linking, suggesting CD20 engages downstream signaling pathways that alter calcium homeostasis rather than functioning as a direct calcium channel.\",\n      \"method\": \"Confocal fluorescent microscopy, surface CD20 quantification, cytochalasin B and PKC inhibitor treatment, calcium signaling assays in normal human B lymphocytes stimulated with CD40L-transfected fibroblasts\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (imaging, pharmacological inhibition, signaling assays) in a single study\",\n      \"pmids\": [\"12938216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD20 cross-linking (CD20XL) induces apoptosis in Ramos B-lymphoma cells via a pathway that can bypass mitochondria and caspase activation: Bcl-2 overexpression blocks cytochrome-c release but does not prevent CD20XL-induced cell death; broad-spectrum caspase inhibitor zVAD-fmk blocks caspase processing but not cell death measured by annexin V/membrane integrity.\",\n      \"method\": \"Cross-linking of CD20 with rituximab in Ramos cells; Bcl-2 overexpression, zVAD-fmk caspase inhibition, mitochondrial membrane potential assays, annexin V/flow cytometry\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic dissection with genetic (Bcl-2 overexpression) and pharmacological (caspase inhibitor) tools, multiple orthogonal readouts\",\n      \"pmids\": [\"12200688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD20 resides in lipid raft domains of the plasma membrane. Rituximab binding to purified CD20 requires an intact disulfide bond between Cys167 and Cys183; reduction and alkylation of CD20 abolishes antibody binding, and reoxidation partially restores it. Intact rituximab shows higher avidity for CD20 on B cells than Fab alone, suggesting cross-linking of CD20 monomers into lipid rafts.\",\n      \"method\": \"Purification of CD20 from E. coli; circular dichroism; rituximab binding affinity measurements; reduction/alkylation/reoxidation; cysteine mutagenesis; comparison of intact Ab vs. Fab affinity on B cells\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified protein reconstitution, mutagenesis, and biochemical validation in single study\",\n      \"pmids\": [\"16285718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The FMC7 monoclonal antibody specifically recognizes CD20; FMC7 binding is abolished by mutations in the extracellular domain of CD20. The FMC7 epitope is a cholesterol-sensitive conformational state of CD20: cholesterol depletion profoundly reduces FMC7 epitope expression while cholesterol enrichment enhances it. FMC7 binding also induces detergent insolubility of CD20, indicating lipid raft association.\",\n      \"method\": \"CD20 ectopic expression in hematopoietic and non-hematopoietic cell lines; extracellular domain mutagenesis; cholesterol depletion/enrichment with methyl-β-cyclodextrin; detergent solubility assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus biochemical lipid raft and cholesterol manipulation assays\",\n      \"pmids\": [\"12835728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TGF-β signaling via Smad proteins directly regulates MS4A1/CD20 transcription in B-cell lymphoma Ramos cells, as shown by ChIP of Smad proteins at the MS4A1 promoter. CD20 knockdown increases apoptosis, while stable CD20 overexpression confers resistance to TGF-β-induced apoptosis, placing CD20 as a survival factor downstream of TGF-β/Smad signaling.\",\n      \"method\": \"Oligonucleotide microarray, chromatin immunoprecipitation (ChIP) for Smad at MS4A1 promoter, siRNA knockdown, stable overexpression, apoptosis assays in Ramos cells and in vivo\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP demonstrating direct Smad binding to MS4A1 promoter, complemented by loss- and gain-of-function experiments\",\n      \"pmids\": [\"22665052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HDAC6 regulates CD20 protein levels post-transcriptionally: HDAC6 inhibition increases CD20 mRNA in the polysomal fraction (enhanced translation) without affecting MS4A1 transcription, demonstrating that HDAC6 controls CD20 expression at the translational level.\",\n      \"method\": \"Pharmacological and genetic HDAC6 inhibition in B-cell tumor lines and primary malignant cells; polysomal fractionation of CD20 mRNA; qRT-PCR for MS4A1 transcription; flow cytometry for CD20 protein; in vivo rituximab survival assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — polysomal fractionation plus genetic knockdown with multiple orthogonal methods, in vitro and in vivo validation\",\n      \"pmids\": [\"28830887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM/X-ray structure of CD20 in complex with rituximab reveals CD20 as a compact double-barrel dimer; two rituximab Fab fragments each engage a composite epitope with an extensive homotypic Fab:Fab interface. The structure suggests rituximab cross-links CD20 into circular assemblies, providing a structural model for complement recruitment.\",\n      \"method\": \"X-ray crystallography of CD20–rituximab complex; structural analysis of CD20 dimer architecture and Fab:Fab interfaces\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional implications, published in Science\",\n      \"pmids\": [\"32079680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structures of full-length CD20 with type I (rituximab, ofatumumab) and type II (obinutuzumab) antibodies reveal distinct interaction mechanisms: type I complexes act as molecular seeds to increase local antibody concentration for efficient complement activation; type II complexes form terminal assemblies that preclude additional mAb/complement recruitment. Ofatumumab type I complexes display optimal geometry for complement recruitment.\",\n      \"method\": \"Cryo-EM structures at 3.7–4.7 Å resolution; binding thermodynamics (ITC); structural comparison of type I vs. type II complexes\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with thermodynamic binding data, mechanistically distinguishing type I vs. II mAb mechanisms\",\n      \"pmids\": [\"32792392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MS4A1/CD20 produces multiple mRNA isoforms with distinct 5' UTRs. The V1 isoform contains upstream open reading frames and a stem-loop structure that cooperatively inhibit polysome recruitment, making it translation-deficient. The V3 isoform lacks these inhibitory elements and correlates with CD20 protein levels. Splice-switching from V3 to V1 mediates CD20 downregulation as a resistance mechanism to anti-CD20 immunotherapy.\",\n      \"method\": \"RNA-seq isoform detection; polysome profiling; morpholino-mediated splice switching; reconstitution of CD20-KO cells with V1 or V3 mRNA; in vitro cytotoxicity with rituximab, CAR-T, and mosunetuzumab; RNA-seq of post-mosunetuzumab relapses\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — polysome profiling plus KO reconstitution plus splice switching, mechanistically explaining isoform-dependent translation\",\n      \"pmids\": [\"37683180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Using super-resolution lattice light-sheet microscopy combined with TDI-DNA-PAINT, CD20 is shown to be abundantly expressed on B-cell microvilli. Binding of therapeutic mAbs (rituximab, ofatumumab, obinutuzumab) leads to antibody concentration-dependent B-cell polarization and stabilization of microvilli protrusions; the oligomeric states of CD20 on microvilli differ by antibody type.\",\n      \"method\": \"Lattice light-sheet microscopy; TDI-DNA-PAINT super-resolution imaging; live immunological B cells; comparison of rituximab, ofatumumab, obinutuzumab\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct super-resolution live-cell imaging with functional (polarization/microvilli stabilization) readout\",\n      \"pmids\": [\"39787234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CD20 C-terminal deletion mutations are associated with significantly reduced CD20 surface expression on lymphoma cells and may contribute to rituximab resistance; truncation of the cytoplasmic C-terminal domain disrupts normal CD20 surface expression.\",\n      \"method\": \"CD20 gene sequencing in 50 lymphoma patients; flow cytometry for CD20 surface expression; correlation of mutation type with expression levels\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — clinical mutation analysis with functional correlation, single-institution study\",\n      \"pmids\": [\"19276251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Rituximab induces cellular senescence in B-cell lymphoma cell lines and primary transformed B cells, associated with elevated intracellular ROS; the ROS scavenger N-acetylcysteine abrogates rituximab-mediated senescence, identifying ROS elevation as a mechanistic driver of anti-CD20-induced senescence.\",\n      \"method\": \"Rituximab treatment of B-cell lymphoma lines; senescence assays; N-acetylcysteine ROS scavenging; adriamycin combination; gene set enrichment analysis in CLL patient dataset\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological rescue experiment (NAC) plus in vitro and clinical data, single lab\",\n      \"pmids\": [\"26880268\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD20 (MS4A1) is a non-glycosylated, multi-phosphorylated tetraspan membrane protein that forms dimers residing in cholesterol-rich lipid raft microdomains on B-cell microvilli; upon cross-linking by antibody or BCR co-stimulation, it facilitates transmembrane Ca2+ movement (downstream of CD19), generates PKC-dependent phosphorylation signals that drive G0→G1 cell cycle entry, and—when engaged by therapeutic anti-CD20 mAbs—induces apoptosis through a Bcl-2/caspase-independent ROS pathway and cellular senescence, while its surface expression is regulated post-transcriptionally by HDAC6-controlled translation and by alternative splicing of the 5' UTR that governs polysome recruitment.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper, then extract discoveries only from KEEP papers.\n\n**Classification summary (key decisions):**\n- Papers about MS4A1/CD20 (B-cell marker, 4-pass TM protein) → KEEP\n- Papers about vitamin B1 (thiamine), aflatoxin B1, Cyclin B1, lamin B1, B1 bradykinin receptor, B1 cells (B-1 lymphocyte subset unrelated to MS4A1), cathelicidin B1, lasso peptide B1, napyradiomycin B1, cyclothiazomycin B1, scavenger receptor B1, class B1 GPCR → EXCLUDE (alias collisions)\n- Papers about cDNA libraries/interactomes that mention MS4A1 incidentally → EXCLUDE unless mechanistic content about MS4A1 specifically\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"Molecular cloning of CD20 (B1/MS4A1) cDNA revealed a predicted protein lacking an N-terminal signal sequence, containing three extensive hydrophobic (transmembrane) regions, a highly charged C-terminal cytoplasmic domain, and no homology to other known proteins. In vitro translation produced a single 33 kDa protein. CD20 was shown to be strongly phosphorylated after CDw40 stimulation.\",\n      \"method\": \"cDNA cloning, in vitro translation, immunoprecipitation, Northern blot\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with direct biochemical validation; foundational structural paper replicated by independent cDNA isolation\",\n      \"pmids\": [\"2456210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"CD20 (B1) cDNA was isolated and its amino acid sequence determined, confirming it is a ~33 kDa phosphoprotein with no signal peptide and three major hydrophobic regions consistent with multiple membrane-spanning domains. Two mRNA species (2.8 and 3.4 kb) arise from alternative splicing.\",\n      \"method\": \"cDNA cloning from tonsillar library, differential hybridization, in vitro translation, limited proteinase digestion peptide mapping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — independent cloning with biochemical validation, peptide mapping confirming identity\",\n      \"pmids\": [\"2448768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"CD20 (B1) is a non-glycosylated phosphoprotein expressed as multiple isoforms (Mr 33,000 and 34,500–36,000). Phosphorylation of B1 is associated with B-cell proliferation: non-proliferating B cells show no 32P incorporation into B1, whereas proliferating/malignant B cells show heavy phosphorylation. Cross-linking B1 on the cell surface with antibody or phorbol ester treatment enhanced phosphorylation. B1(35) contains both phosphoserine and phosphothreonine, while B1(33) contains only phosphoserine, and these isoforms are generated by differential phosphorylation.\",\n      \"method\": \"32P metabolic labeling, immunoprecipitation, peptide mapping, alkaline phosphatase treatment, PMA stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical characterization with multiple orthogonal methods; mechanistic link between phosphorylation state and proliferation established\",\n      \"pmids\": [\"2454914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"CD20 is a non-glycosylated phosphoprotein: endoglycosidase digestion and tunicamycin labeling confirmed neither the 33 kDa nor the 34,500–36,000 Mr forms are glycosylated. PMA treatment selectively increases phosphorylation and abundance of the 34,500–36,000 Mr form, indicating phosphorylation underlies the molecular weight heterogeneity.\",\n      \"method\": \"Biosynthetic labeling with [35S]methionine, endoglycosidase digestion, tunicamycin treatment, PMA stimulation, immunoprecipitation\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical experiment with multiple orthogonal methods confirming non-glycosylated status and phosphorylation-driven heterogeneity\",\n      \"pmids\": [\"2467190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Stable transfection of CD20 cDNA into non-B cell lines (T lymphoblastoid, pre-B lymphoblastoid, K562 erythroleukemia, NIH-3T3 fibroblasts) specifically increased transmembrane Ca2+ conductance as measured by whole-cell patch clamp. Antibody cross-linking of CD20 on lymphoblastoid cells enhanced the same Ca2+ conductance. Biochemical cross-linking suggested CD20 exists as a multimeric oligomer in the membrane, consistent with ion channel formation.\",\n      \"method\": \"Stable cDNA transfection, whole-cell patch clamp electrophysiology, fluorescence microscopy of cytosolic Ca2+, chemical cross-linking, immunoprecipitation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in multiple heterologous cell types with direct electrophysiological measurement; strong functional evidence for Ca2+ conductance role\",\n      \"pmids\": [\"7684739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Anti-B1 (anti-CD20) monoclonal antibodies stimulate resting tonsillar B cells to transition from G0 to G1 phase of the cell cycle, inducing RNA synthesis and growth factor responsiveness but not S-phase entry or mitosis. This activation is inhibited by cyclosporin A (I50 ~50 ng/ml), implicating early activation pathways. Both activatory and inhibitory (of Ig secretion) effects of anti-CD20 depend on distinct epitopes.\",\n      \"method\": \"B cell proliferation assays, RNA synthesis measurement (3H-uridine), thymidine incorporation, flow cytometry, cyclosporin A inhibition\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean functional experiment with defined cellular phenotype (G0→G1 transition) and pharmacological validation\",\n      \"pmids\": [\"2415587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Cross-linking of Bp35 (CD20) on the B-cell surface by intact antibody (but not monovalent Fab) is required to trigger B-cell proliferation, indicating that receptor aggregation/multimerization is a mechanistic requirement for CD20-mediated B-cell activation.\",\n      \"method\": \"B-cell proliferation assays with intact antibody vs. Fab fragments, blocking experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean functional dissection using Fab vs. intact antibody; cross-linking requirement clearly established\",\n      \"pmids\": [\"3872456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"The B1 (CD20) molecule is a 32 kDa phosphorylated cell surface protein expressed exclusively from mid pre-B to plasma cell stage. Anti-B1 antibody inhibits B-cell proliferation induced by anti-μ, Staphylococcus aureus Cowan 1, activated T cells, and Epstein-Barr virus, but does not activate B cells itself. Inhibition requires continuous presence of antibody and is maximal when added at culture initiation, suggesting CD20 plays a role in regulating early B-cell activation rather than growth factor-dependent proliferation of pre-activated cells.\",\n      \"method\": \"Anti-B1 antibody blocking assays, thymidine incorporation, Ig secretion (pokeweed mitogen), co-culture experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple stimulation conditions tested with rigorous controls; functional role in B-cell activation established\",\n      \"pmids\": [\"3925015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD20 crosslinking (CD20XL) induces apoptosis in Burkitt lymphoma Ramos cells through a pathway that is distinct from CD95 and BCR-mediated apoptosis: it does not require active caspases (broad-spectrum caspase inhibitor zVAD-fmk blocked caspase processing but not cell death) and cannot be blocked by Bcl-2 overexpression (which blocked cytochrome c release but not CD20XL-induced death), demonstrating a caspase- and mitochondria-independent cell death pathway.\",\n      \"method\": \"Caspase inhibitor (zVAD-fmk) treatment, Bcl-2 overexpression, annexin V staining, mitochondrial membrane potential assay, cytochrome c release, flow cytometry\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genetic and pharmacological approaches in same cell system; pathway independence clearly demonstrated\",\n      \"pmids\": [\"12200688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The ability of anti-CD20 mAbs to activate complement-dependent lysis correlates with their capacity to translocate CD20 into lipid raft (detergent-insoluble) membrane microdomains. mAb B1, which cannot translocate CD20 into rafts, is unable to recruit complement, whereas rituximab and 1F5, which translocate CD20 into rafts, effectively recruit complement. Hyper-cross-linking drove B1 and other mAbs into detergent-insoluble fractions and conferred complement activation ability, directly linking raft residency to complement function.\",\n      \"method\": \"Membrane fractionation (sucrose gradient), complement lysis assays, hyper-cross-linking with F(ab')2 anti-Ig, panel of anti-B-cell mAbs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic link between lipid raft translocation and complement activation established with multiple mAbs and cross-linking rescue experiment\",\n      \"pmids\": [\"12393541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD20 is resident in lipid raft (detergent-insoluble) membrane domains. CD40 stimulation of normal human B lymphocytes causes rapid, time- and concentration-dependent internalization of CD20 via translocation into lipid rafts and subsequent uptake into cytoplasmic vesicles. This process is inhibited by cytochalasin B and protein kinase C antagonists. Paradoxically, CD20 down-regulation via CD40 activation enhanced calcium signaling upon subsequent CD20 cross-linking, suggesting CD20 engages downstream signaling pathways that modulate calcium homeostasis rather than functioning as a direct calcium channel.\",\n      \"method\": \"Confocal fluorescent microscopy, flow cytometry, cytochalasin B inhibition, PKC antagonists, calcium signaling assays, RT-PCR for mRNA stability\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live imaging and pharmacological dissection with defined signaling readout; multiple orthogonal approaches\",\n      \"pmids\": [\"12938216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Ectopic expression of CD20 in Chinese hamster ovary cells introduced a novel store-operated cation (SOC) entry pathway permeable to both Ca2+ and Sr2+. Deletion of a cytoplasmic sequence in CD20 essential for raft localization abolished this SOC activity. In B cells, BCR-stimulated Ca2+ influx was significantly reduced by CD20 downregulation (siRNA) and by cholesterol depletion, establishing raft-associated CD20 as a component of the BCR-activated SOC entry pathway.\",\n      \"method\": \"Ectopic expression in CHO cells, domain deletion mutagenesis, Sr2+/Ca2+ influx assays, siRNA knockdown of CD20, cholesterol depletion (methyl-β-cyclodextrin), B-cell receptor stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution in heterologous cells + mutagenesis + siRNA knockdown in native B cells; strong mechanistic evidence\",\n      \"pmids\": [\"12920111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In CD20-deficient (CD20−/−) mouse B cells, CD19-induced intracellular calcium responses were significantly reduced compared to wild-type, with a less dramatic effect on IgM-induced responses, establishing a role for CD20 in facilitating transmembrane Ca2+ movement in primary B cells. Immature and mature B-cell IgM expression was ~20–30% lower in CD20−/− mice. B-cell development, tissue localization, signal transduction, proliferation, T cell-dependent antibody responses, and affinity maturation were otherwise normal.\",\n      \"method\": \"CD20−/− mouse generation and analysis, intracellular calcium flux assays (CD19 and IgM cross-linking), flow cytometry panel\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with defined calcium signaling phenotype; complementary to human CD20 transfection data\",\n      \"pmids\": [\"14688067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Purified human CD20 expressed in E. coli localizes to the cell membrane and has substantial α-helical secondary structure by circular dichroism spectroscopy. Rituximab binds purified CD20 with nanomolar affinity in a manner abolished by reduction and alkylation, with data consistent with the antibody epitope being within the disulfide-bonded loop formed between cysteine residues C167 and C183. Intact rituximab shows much higher affinity for CD20 on B cells than for isolated CD20, suggesting B cells display CD20 such that avidity effects occur through cross-linking of CD20 monomers, possibly into lipid rafts.\",\n      \"method\": \"E. coli expression, detergent purification, circular dichroism spectroscopy, surface plasmon resonance (binding kinetics), reduction/alkylation mutagenesis, reoxidation experiments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified protein characterization with mutagenesis and direct binding measurements; identifies disulfide-bonded epitope loop\",\n      \"pmids\": [\"16285718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Type I anti-CD20 mAbs (e.g., rituximab) but not Type II mAbs induce cytosolic Ca2+ flux in B cells, and this requires B-cell antigen receptor (BCR) expression. Type I mAb binding causes direct physical association of CD20 with the BCR (measured by FRET), and phosphorylation of BCR-specific adaptor proteins BLNK and SLP-76. The Ca2+ flux is inhibited by Syk, Src, and PI3K inhibitors but not EGTA, p38, or ERK1/2 inhibitors. BCR-negative Ramos variant cells expressing normal CD20 levels completely fail to flux Ca2+ upon CD20 ligation, demonstrating that CD20-induced Ca2+ signaling is BCR-dependent.\",\n      \"method\": \"FRET analysis, calcium flux assays, pharmacological inhibitor panel (Syk, Src, PI3K, EGTA, p38, ERK1/2), Western blot for BLNK/SLP-76 phosphorylation, BCR-negative Ramos cell variant, Type I vs. Type II mAb comparison\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — FRET demonstrating direct CD20-BCR association, pharmacological pathway dissection, genetic (BCR-null) validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"18426802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A patient with homozygous splice-junction mutation in MS4A1 (CD20 gene) resulting in nonfunctional mRNA and absent CD20 protein showed severely impaired T cell-independent (TI) antibody responses after vaccination with TI antigens, while antigen-independent B-cell development was normal. Consistent results were obtained in CD20-deficient mice for TI antipolysaccharide B-cell responses, establishing CD20 as specifically required for TI humoral immunity.\",\n      \"method\": \"Human genetic analysis (homozygous MS4A1 splice mutation), patient immunophenotyping, vaccination response assays, CD20−/− mouse TI antigen challenge\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function (natural mutation) corroborated by mouse knockout; specific phenotype (TI antibody deficiency) with normal B-cell development\",\n      \"pmids\": [\"20038800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Epitope mapping and X-ray crystallography of the obinutuzumab (GA101, Type II) Fab fragment alone and in complex with a CD20 cyclopeptide revealed that Type I and Type II antibodies recognize overlapping epitopes on CD20's extracellular loop but bind in completely different orientations. GA101's elbow angle is ~30° wider than Type I antibodies, resulting in different spatial arrangements of the two CD20 molecules bound per antibody. Protein tomography and confocal microscopy showed different CD20 membrane complexes and different membrane compartmentalization for Type I vs. Type II antibodies.\",\n      \"method\": \"X-ray crystallography (Fab alone and Fab-CD20 cyclopeptide complex), epitope fine-mapping, protein tomography, confocal microscopy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with orthogonal tomography and microscopy; mechanistic structural basis for Type I/II distinction established\",\n      \"pmids\": [\"21444918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TGF-β induces apoptosis of B-cell lymphoma Ramos cells through direct transcriptional repression of MS4A1/CD20 by Smad proteins: chromatin immunoprecipitation (ChIP) showed Smad proteins directly bound the MS4A1 promoter upon TGF-β stimulation, reducing CD20 transcription. CD20 knockdown phenocopied TGF-β-induced apoptosis, while stable CD20 overexpression conferred resistance to TGF-β-induced apoptosis, establishing CD20 as a survival factor downstream of TGF-β/Smad signaling.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for Smad at MS4A1 promoter, oligonucleotide microarray, siRNA knockdown, stable overexpression, apoptosis assays in vitro and in vivo xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP directly linking Smad to MS4A1 promoter, functional rescue by overexpression and phenocopy by knockdown; multiple orthogonal methods\",\n      \"pmids\": [\"22665052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HDAC6 regulates CD20 protein levels post-transcriptionally: HDAC6 inhibition significantly increases CD20 protein in B-cell tumor lines and primary malignant cells without affecting MS4A1 mRNA transcription. HDAC6 inhibition enhances CD20 mRNA translation, shown by increased CD20 mRNA in the polysomal fraction, indicating HDAC6 controls CD20 at the level of mRNA translation. Combined HDAC6 inhibition with anti-CD20 mAbs improved in vitro cytotoxicity and mouse survival.\",\n      \"method\": \"Pharmacological HDAC6 inhibition, HDAC6 siRNA/shRNA knockdown, flow cytometry for CD20 surface expression, RT-PCR for MS4A1 mRNA, polysome fractionation, in vivo mouse rituximab survival model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic approaches with polysome profiling directly demonstrating translational control; mechanistic novelty confirmed by multiple orthogonal methods\",\n      \"pmids\": [\"28830887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structure of full-length CD20 in complexes with rituximab (Type I) and ofatumumab (Type I) and obinutuzumab (Type II) at 3.7–4.7 Å resolution revealed that CD20 is a compact double-barrel dimer. Two rituximab Fab fragments each engage a composite epitope with an extensive homotypic Fab:Fab interface. Type II mAb obinutuzumab forms terminal complexes preventing recruitment of additional mAbs and complement components, while Type I complexes act as molecular seeds that increase local mAb concentration for efficient complement activation. Ofatumumab complexes display optimal geometry for complement recruitment.\",\n      \"method\": \"Cryo-electron microscopy structure determination, binding thermodynamics (ITC/SPR), structural modeling\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures at near-atomic resolution with thermodynamic validation; definitive structural basis for Type I/II mechanisms\",\n      \"pmids\": [\"32792392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structure of CD20 in complex with rituximab revealed CD20 as a compact double-barrel dimer bound by two RTX Fab fragments, each engaging a composite epitope with an extensive homotypic Fab:Fab interface. The structure suggests RTX cross-links CD20 into circular assemblies on the B-cell surface and provides a structural model for complement recruitment, explaining the mechanism of complement-dependent cytotoxicity.\",\n      \"method\": \"Cryo-EM structure determination\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic-resolution cryo-EM structure; first structure of CD20 protein itself\",\n      \"pmids\": [\"32079680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Flow cytometric energy transfer (FRET) analysis demonstrated that CD20 at the B-cell surface is in close proximity (within 2–10 nm) to MHC class I, MHC class II (DR, DQ), and tetraspan molecules CD53, CD81, and CD82 in a single supramolecular complex, suggesting CD20 participates in multicomponent membrane assemblies that may be involved in signaling and antigen presentation.\",\n      \"method\": \"Flow cytometric FRET with fluorescently labeled antibodies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — FRET proximity data is supportive but not biochemical co-IP; single lab, no functional follow-up in this study\",\n      \"pmids\": [\"8816400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The FMC7 monoclonal antibody specifically recognizes CD20 expressed in multiple cell lines, and this reactivity is abolished by mutations in the extracellular domain of CD20. The FMC7 epitope on CD20 is exceptionally sensitive to membrane cholesterol: cholesterol depletion profoundly reduces FMC7 epitope expression, while cholesterol enrichment enhances it, indicating that a cholesterol-dependent conformational state of CD20 exists in the plasma membrane.\",\n      \"method\": \"Ectopic CD20 expression in hematopoietic and non-hematopoietic cell lines, extracellular domain mutation analysis, cholesterol depletion (methyl-β-cyclodextrin) and enrichment, flow cytometry\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis and cholesterol manipulation with clear functional readout; single lab but multiple cell systems\",\n      \"pmids\": [\"12835728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MS4A1/CD20 mRNA is produced as multiple isoforms with distinct 5' UTRs (V1–V4). V1, the most abundant isoform, contains upstream open reading frames (uORFs) and a stem-loop structure that cooperatively inhibit polysome recruitment, rendering V1 translation-deficient. V3 is the translation-competent isoform and correlates with CD20 protein levels in DLBCL. Reconstitution of CD20-knockout cells with V3 mRNA restored CD20 surface expression; V1 reconstitution produced undetectable CD20 protein. Splice-switching morpholino oligomers redirecting splicing from V1 to V3 enhanced CD20 expression and rituximab-mediated cytotoxicity. V3→V1 splicing shift was identified in post-mosunetuzumab relapsed follicular lymphoma samples.\",\n      \"method\": \"RNA sequencing, ribosome profiling/polysome analysis, morpholino splice-switching, CD20-knockout cell reconstitution with V1 or V3 mRNA, flow cytometry, cytotoxicity assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution experiments (V1 vs. V3 in KO cells) + polysome profiling + clinical splice-shift validation; multiple orthogonal methods; mechanistically resolves post-transcriptional regulation of CD20\",\n      \"pmids\": [\"37683180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Using TDI-DNA-PAINT combined with lattice light-sheet microscopy on live B cells, endogenous CD20 was found to be abundantly expressed on microvilli. Therapeutic mAbs (rituximab, ofatumumab, obinutuzumab) bind CD20 on microvilli in an antibody concentration-dependent manner, leading to B-cell polarization and stabilization of microvilli protrusions. Different mAbs produced distinct oligomeric states of CD20 on the cell surface.\",\n      \"method\": \"TDI-DNA-PAINT super-resolution microscopy, lattice light-sheet (LLS) microscopy, live B-cell imaging\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel super-resolution imaging with functional consequence (polarization); single lab, methodology is novel but functional validation is limited\",\n      \"pmids\": [\"39787234\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD20 (MS4A1) is a non-glycosylated, phosphorylated tetraspan membrane protein that exists as a double-barrel dimer in lipid raft microdomains of B-cell membranes; it regulates transmembrane Ca2+ conductance and store-operated Ca2+ entry by associating with and activating the B-cell antigen receptor (BCR) signaling cascade (requiring Syk, Src, and PI3K), promotes B-cell transition from G0 to G1, is required for T cell-independent antibody responses, undergoes differential phosphorylation that correlates with proliferative state, has its protein levels post-transcriptionally regulated by HDAC6-dependent translational control and by alternative 5'-UTR splicing (V1 isoform contains inhibitory uORFs/stem-loop; V3 is translation-competent), and is subject to direct transcriptional repression by TGF-β/Smad signaling; its translocation into lipid rafts upon Type I mAb ligation determines complement-dependent cytotoxicity, while Type II mAbs bind CD20 in a distinct orientation forming terminal complexes that preclude complement recruitment.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MS4A1 (CD20) is a non-glycosylated, multiply phosphorylated tetraspan membrane protein that functions as a signal transducer on B lymphocytes, coupling receptor cross-linking to calcium mobilization and cell cycle progression. CD20 resides as a compact double-barrel dimer in cholesterol-rich lipid raft microdomains on B-cell microvilli, and bivalent antibody engagement triggers receptor aggregation that generates PKC-dependent phosphorylation signals driving G0→G1 transition [PMID:3872456, PMID:2415587, PMID:2454914]; CD20 facilitates transmembrane Ca²⁺ flux downstream of CD19 signaling, as demonstrated in CD20-knockout mice [PMID:9634476, PMID:14688067]. Structural studies reveal that type I therapeutic antibodies (rituximab, ofatumumab) seed oligomeric CD20 assemblies that recruit complement, whereas type II antibodies (obinutuzumab) form terminal complexes precluding further complement binding, and anti-CD20 engagement can also induce Bcl-2/caspase-independent apoptosis through ROS-mediated pathways [PMID:32792392, PMID:12200688, PMID:26880268]. CD20 surface expression is controlled post-transcriptionally by HDAC6-regulated polysome loading and by alternative 5′ UTR splicing, wherein a translation-deficient V1 isoform harboring inhibitory upstream ORFs and stem-loops mediates CD20 downregulation as a resistance mechanism to anti-CD20 immunotherapy [PMID:28830887, PMID:37683180].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Establishing that CD20 engagement transduces a B-cell activation signal requiring receptor aggregation answered the fundamental question of whether CD20 is a passive marker or an active signaling molecule.\",\n      \"evidence\": \"Monoclonal antibody vs. Fab fragment stimulation assays on tonsillar B cells; proliferation and G0→G1 transition readouts\",\n      \"pmids\": [\"3872456\", \"2415587\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Downstream intracellular signaling intermediates were unidentified\",\n        \"Whether CD20 signals autonomously or requires co-receptors was unknown\"\n      ]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Demonstrating that CD20 and CD40 trigger distinct, synergistic activation programs revealed that CD20 specifically initiates G0→G1 entry rather than acting redundantly with other B-cell surface molecules.\",\n      \"evidence\": \"Combined anti-CD20/anti-CD40 stimulation of purified tonsillar B cells with proliferation readouts\",\n      \"pmids\": [\"3487090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular basis for synergy between CD20 and CD40 pathways was undefined\",\n        \"Downstream signaling nodes distinguishing the two pathways were unknown\"\n      ]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Identifying CD20 as a non-glycosylated phosphoprotein whose phosphorylation is enhanced by PKC activation linked CD20 cross-linking to a defined kinase signaling pathway.\",\n      \"evidence\": \"³²P metabolic labeling, peptide mapping, PMA/DAG stimulation, endoglycosidase/tunicamycin treatment in B-cell lines\",\n      \"pmids\": [\"2454914\", \"2467190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific phosphorylation sites and their functional significance were unmapped\",\n        \"Identity of kinases directly phosphorylating CD20 was unknown\"\n      ]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"CD20-knockout mice revealed that CD20 facilitates transmembrane Ca²⁺ movement downstream of CD19, resolving a long-standing question about CD20's ion-conducting role in primary cells.\",\n      \"evidence\": \"CD20⁻/⁻ mouse model; intracellular calcium flux measurements in primary B cells stimulated via CD19 or IgM\",\n      \"pmids\": [\"9634476\", \"14688067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether CD20 itself is the calcium channel or acts indirectly remained unresolved\",\n        \"Molecular mechanism linking CD20 to Ca²⁺ entry was undefined\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that CD20 cross-linking induces apoptosis through a Bcl-2- and caspase-independent pathway established a non-canonical cell death mechanism relevant to anti-CD20 immunotherapy.\",\n      \"evidence\": \"Rituximab cross-linking of Ramos cells; Bcl-2 overexpression and zVAD-fmk caspase inhibition with annexin V/mitochondrial readouts\",\n      \"pmids\": [\"12200688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the caspase-independent effector mediating cell death was unknown\",\n        \"Relevance to in vivo therapeutic killing was not established\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing that CD20 resides in cholesterol-sensitive lipid raft microdomains and that CD40 stimulation triggers its internalization connected CD20's signaling to its membrane microdomain organization.\",\n      \"evidence\": \"Cholesterol depletion/enrichment, detergent solubility, confocal microscopy, and PKC inhibitor studies in B cells and cell lines\",\n      \"pmids\": [\"12835728\", \"12938216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular determinants targeting CD20 to lipid rafts were unknown\",\n        \"Relationship between raft localization and calcium signaling was not defined\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying TGF-β/Smad as a direct transcriptional regulator of MS4A1 and showing that CD20 confers resistance to TGF-β-induced apoptosis placed CD20 within a survival signaling axis in B-cell lymphoma.\",\n      \"evidence\": \"ChIP of Smad at MS4A1 promoter; siRNA knockdown and stable overexpression in Ramos cells; in vivo validation\",\n      \"pmids\": [\"22665052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Smad regulation of CD20 operates in normal B-cell development was untested\",\n        \"Downstream effectors of CD20-mediated survival signaling were not identified\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealing that rituximab induces ROS-dependent cellular senescence identified a distinct anti-tumor mechanism beyond direct apoptosis for anti-CD20 therapy.\",\n      \"evidence\": \"Rituximab treatment of B-lymphoma lines; senescence assays with N-acetylcysteine rescue\",\n      \"pmids\": [\"26880268\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Source of ROS (mitochondrial vs. NADPH oxidase) was not determined\",\n        \"Whether senescence occurs in vivo during anti-CD20 therapy was not demonstrated\",\n        \"Single-laboratory finding without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovering that HDAC6 controls CD20 protein levels by regulating polysome recruitment of MS4A1 mRNA revealed a post-transcriptional regulatory layer governing CD20 surface expression.\",\n      \"evidence\": \"HDAC6 inhibition (pharmacological and genetic) in B-cell tumor lines; polysomal fractionation; in vivo rituximab efficacy\",\n      \"pmids\": [\"28830887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific HDAC6 substrate(s) mediating translational control were not identified\",\n        \"Whether HDAC6 regulation operates in normal B cells was untested\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"High-resolution structures of CD20 with type I and type II antibodies explained how antibody geometry determines complement activation versus direct killing, providing a structural framework for therapeutic antibody design.\",\n      \"evidence\": \"X-ray crystallography and cryo-EM at 3.7–4.7 Å of CD20–rituximab, CD20–ofatumumab, and CD20–obinutuzumab complexes; ITC binding thermodynamics\",\n      \"pmids\": [\"32079680\", \"32792392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structure of CD20 in the absence of antibody was not resolved\",\n        \"Whether CD20 forms higher-order oligomers on the native membrane without antibody was unknown\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that alternative 5′ UTR splicing switches MS4A1 mRNA between translationally competent and incompetent isoforms identified a mechanism of CD20 loss driving resistance to anti-CD20 immunotherapy.\",\n      \"evidence\": \"Polysome profiling; morpholino splice switching; CD20-KO reconstitution with V1 vs. V3 isoforms; cytotoxicity assays; RNA-seq of post-therapy relapses\",\n      \"pmids\": [\"37683180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Trans-acting factors governing V1/V3 splice choice were not identified\",\n        \"Whether pharmacological splice correction can restore CD20 and therapeutic sensitivity in vivo was untested\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Super-resolution imaging of CD20 on B-cell microvilli revealed that therapeutic antibodies concentrate and stabilize microvilli protrusions in an antibody-type-dependent manner, providing a nanoscale spatial context for anti-CD20 effector mechanisms.\",\n      \"evidence\": \"Lattice light-sheet microscopy and TDI-DNA-PAINT on live B cells with rituximab, ofatumumab, and obinutuzumab\",\n      \"pmids\": [\"39787234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional consequences of microvilli stabilization for complement or effector cell engagement were not determined\",\n        \"Whether microvilli distribution of CD20 differs between normal and malignant B cells was not addressed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether CD20 functions directly as an ion channel or indirectly modulates calcium entry through protein–protein interactions remains structurally and electrophysiologically unresolved, and the identity of the trans-acting factors governing pathological V1/V3 splice switching is unknown.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No electrophysiological recording of purified CD20 reconstituted in lipid bilayers exists\",\n        \"Trans-acting splicing regulators controlling the V1/V3 switch are unidentified\",\n        \"Structural basis for CD20 calcium conductance or modulation is absent\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2, 5, 6]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [5, 6, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [9, 10, 16]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0006089\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 5, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 6, 7, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [8, 18]}\n    ],\n    \"complexes\": [\n      \"CD20 homodimer\"\n    ],\n    \"partners\": [\n      \"CD19\",\n      \"CD40\",\n      \"SMAD2\",\n      \"SMAD3\",\n      \"HDAC6\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CD20 (MS4A1) is a non-glycosylated, differentially phosphorylated tetraspan membrane protein that functions as a compact double-barrel dimer in lipid raft microdomains of B lymphocytes, where it regulates store-operated calcium entry and couples to B-cell antigen receptor (BCR) signaling through Syk, Src, and PI3K kinases to promote B-cell activation from G0 to G1 [PMID:7684739, PMID:12920111, PMID:18426802, PMID:2415587]. Homozygous loss-of-function mutations in MS4A1 cause selective deficiency of T cell-independent antibody responses while leaving B-cell development intact [PMID:20038800]. Cryo-EM structures reveal that Type I anti-CD20 monoclonal antibodies (rituximab, ofatumumab) cross-link CD20 dimers into assemblies that seed complement recruitment, whereas Type II antibodies (obinutuzumab) form terminal complexes that preclude complement activation, explaining their divergent cytotoxic mechanisms [PMID:32079680, PMID:32792392]. CD20 protein levels are controlled post-transcriptionally by HDAC6-dependent translational regulation and by alternative 5′-UTR splicing—the V1 isoform contains inhibitory uORFs and a stem-loop that suppress translation, while V3 is the translation-competent form—and transcriptionally by TGF-β/Smad-mediated repression of the MS4A1 promoter [PMID:28830887, PMID:37683180, PMID:22665052].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Establishing that CD20 has a direct role in B-cell activation: antibody cross-linking of CD20 drives resting B cells from G0 to G1, while monovalent Fab fragments are inactive, demonstrating that receptor aggregation is the mechanistic trigger for activation signaling.\",\n      \"evidence\": \"B-cell proliferation assays with intact antibody versus Fab fragments, cyclosporin A inhibition, and multi-stimulus blocking experiments on tonsillar B cells\",\n      \"pmids\": [\"2415587\", \"3872456\", \"3925015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway from CD20 aggregation was unknown\", \"Whether CD20 functions as an intrinsic signaling receptor or accessory molecule was unresolved\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Molecular cloning and biochemical characterization revealed CD20 as a non-glycosylated phosphoprotein with multiple transmembrane domains and no homology to known proteins, with differential phosphorylation (serine and threonine) correlating with B-cell proliferative state.\",\n      \"evidence\": \"cDNA cloning from two independent groups, in vitro translation, 32P metabolic labeling, endoglycosidase digestion, tunicamycin treatment, PMA stimulation\",\n      \"pmids\": [\"2456210\", \"2448768\", \"2454914\", \"2467190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of kinases phosphorylating CD20 was unknown\", \"Functional consequence of individual phosphorylation sites was not mapped\", \"Membrane topology was inferred from hydropathy, not experimentally determined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Reconstitution of CD20 in multiple non-B cell lines demonstrated that CD20 directly increases transmembrane Ca²⁺ conductance, and chemical cross-linking revealed CD20 exists as a multimer consistent with ion channel or channel-regulatory function.\",\n      \"evidence\": \"Stable cDNA transfection into T cells, pre-B cells, K562, and NIH-3T3; whole-cell patch clamp electrophysiology; chemical cross-linking and immunoprecipitation\",\n      \"pmids\": [\"7684739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD20 itself forms a pore or activates an endogenous channel was unresolved\", \"Ion selectivity and single-channel properties were not characterized\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"FRET analysis revealed CD20 resides within 2–10 nm of MHC class I, MHC class II, and tetraspanins CD53/CD81/CD82, suggesting it participates in supramolecular membrane signaling complexes.\",\n      \"evidence\": \"Flow cytometric energy transfer with fluorescently labeled antibodies on B cells\",\n      \"pmids\": [\"8816400\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Proximity data did not confirm direct physical interaction\", \"Functional significance of CD20–tetraspanin association was not tested\", \"No reciprocal co-immunoprecipitation was performed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"CD20 cross-linking was shown to induce a caspase- and Bcl-2-independent apoptotic pathway, and separately, the ability of anti-CD20 mAbs to activate complement was mechanistically linked to their capacity to translocate CD20 into lipid raft microdomains.\",\n      \"evidence\": \"Caspase inhibitor and Bcl-2 overexpression experiments in Ramos cells; membrane fractionation and complement lysis assays with Type I and Type II mAb panels; hyper-cross-linking rescue\",\n      \"pmids\": [\"12200688\", \"12393541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the caspase-independent death effector was unknown\", \"Whether raft residency was necessary for all CD20 effector functions beyond complement was untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"CD20 was established as a component of the BCR-activated store-operated calcium (SOC) entry pathway: ectopic expression in CHO cells introduced SOC activity dependent on a raft-targeting cytoplasmic domain, and siRNA knockdown in B cells reduced BCR-stimulated Ca²⁺ influx. Cholesterol-dependent conformational states of CD20 were also demonstrated.\",\n      \"evidence\": \"Reconstitution in CHO cells with deletion mutagenesis, siRNA knockdown in B cells, cholesterol depletion/enrichment, Ca²⁺/Sr²⁺ influx assays, CD40-stimulated internalization microscopy\",\n      \"pmids\": [\"12920111\", \"12835728\", \"12938216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the SOC channel activated by CD20 was not determined\", \"Whether CD20 is the pore-forming subunit or an accessory/regulatory subunit remained open\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"CD20-knockout mice confirmed a physiological role for CD20 in transmembrane Ca²⁺ signaling—particularly CD19-induced responses—while revealing that B-cell development and T cell-dependent immunity are largely CD20-independent.\",\n      \"evidence\": \"CD20⁻/⁻ mouse generation, intracellular calcium flux upon CD19 and IgM cross-linking, flow cytometry phenotyping\",\n      \"pmids\": [\"14688067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"T cell-independent responses in CD20⁻/⁻ mice were not tested in this study\", \"Mechanism linking CD20 to CD19-specific calcium signaling was not identified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Structural characterization of purified CD20 revealed substantial α-helical content and showed that the rituximab epitope requires a disulfide bond between C167 and C183 in the extracellular loop, with avidity effects on intact B cells suggesting CD20 multimerization on the cell surface.\",\n      \"evidence\": \"E. coli expression and purification, circular dichroism spectroscopy, surface plasmon resonance, reduction/alkylation mutagenesis\",\n      \"pmids\": [\"16285718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure was yet available\", \"Stoichiometry of native CD20 complexes on B cells was unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The mechanism of CD20-induced Ca²⁺ signaling was resolved: Type I mAbs cause direct physical association of CD20 with the BCR (by FRET), activate BLNK/SLP-76 phosphorylation, and require Syk, Src, and PI3K—BCR-negative cells expressing normal CD20 completely fail to signal, demonstrating CD20 Ca²⁺ flux is BCR-dependent rather than intrinsic channel activity.\",\n      \"evidence\": \"FRET for CD20–BCR proximity, pharmacological kinase inhibitor panel, BCR-negative Ramos variant, Western blot for adaptor phosphorylation\",\n      \"pmids\": [\"18426802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CD20 physically engages the BCR complex was not structurally resolved\", \"Whether CD20 directly contacts BCR or requires an intermediary was unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A human loss-of-function mutation in MS4A1 established CD20 as specifically required for T cell-independent antibody responses, the first Mendelian phenotype linked to CD20 deficiency.\",\n      \"evidence\": \"Homozygous splice-junction mutation in a patient, vaccination response assays for TI antigens, corroboration in CD20⁻/⁻ mice\",\n      \"pmids\": [\"20038800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CD20 specifically enables TI responses was not elucidated\", \"Whether the phenotype extends to other TI antigen classes was not fully tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"X-ray crystallography of the obinutuzumab Fab–CD20 peptide complex revealed that Type I and Type II mAbs bind overlapping epitopes in completely different orientations, explaining their divergent capacities for complement activation and raft redistribution.\",\n      \"evidence\": \"X-ray crystallography of Fab alone and Fab–cyclopeptide complex, protein tomography, confocal microscopy\",\n      \"pmids\": [\"21444918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure was of Fab with a cyclopeptide, not full-length membrane-embedded CD20\", \"Orientation differences did not explain direct homotypic killing by Type II mAbs\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"TGF-β/Smad signaling was shown to directly repress MS4A1 transcription by Smad binding at the promoter, and CD20 knockdown phenocopied TGF-β-induced apoptosis while overexpression conferred resistance, establishing CD20 as a Smad-regulated survival factor.\",\n      \"evidence\": \"ChIP for Smad at MS4A1 promoter, siRNA knockdown, stable overexpression, apoptosis assays in vitro and in vivo xenograft\",\n      \"pmids\": [\"22665052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Smad-mediated CD20 repression operates in normal B cells beyond lymphoma was untested\", \"Whether CD20's survival function is calcium-dependent was not determined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"HDAC6 was identified as a post-transcriptional regulator of CD20: HDAC6 inhibition increases CD20 protein without affecting mRNA levels, by enhancing MS4A1 mRNA loading onto polysomes—revealing a translational control mechanism with therapeutic implications for anti-CD20 therapy.\",\n      \"evidence\": \"Pharmacological and genetic HDAC6 inhibition, polysome fractionation, flow cytometry, in vivo rituximab survival model\",\n      \"pmids\": [\"28830887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The HDAC6 substrate mediating translational control of CD20 mRNA was not identified\", \"Whether HDAC6 acts via the 5′-UTR splicing mechanism was unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Cryo-EM structures of full-length CD20 in complex with rituximab, ofatumumab, and obinutuzumab at 3.7–4.7 Å resolution defined CD20 as a compact double-barrel dimer and revealed that Type I mAbs cross-link dimers into supramolecular assemblies that seed complement, while Type II mAbs form terminal complexes that preclude complement recruitment.\",\n      \"evidence\": \"Cryo-EM structure determination with ITC/SPR binding thermodynamics\",\n      \"pmids\": [\"32079680\", \"32792392\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of CD20 in its native lipid environment or without mAb was obtained\", \"Whether oligomeric assemblies form on live cell membranes at physiological mAb concentrations was not proven\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Alternative 5′-UTR splicing of MS4A1 mRNA was revealed as a major determinant of CD20 protein expression: the abundant V1 isoform contains inhibitory uORFs and a stem-loop that block translation, while V3 is translation-competent, and V1-to-V3 splice-switching enhanced CD20 surface expression and rituximab efficacy.\",\n      \"evidence\": \"RNA sequencing, ribosome profiling, morpholino splice-switching, CD20-KO reconstitution with V1 or V3, clinical relapse sample analysis\",\n      \"pmids\": [\"37683180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors controlling V1/V3 splice choice were not identified\", \"Relationship between HDAC6-mediated translational control and 5′-UTR isoform usage was not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Super-resolution imaging localized endogenous CD20 to B-cell microvilli and showed that therapeutic mAbs induce distinct oligomeric states and B-cell polarization, adding a spatial dimension to understanding of mAb mechanism of action.\",\n      \"evidence\": \"TDI-DNA-PAINT and lattice light-sheet microscopy on live B cells\",\n      \"pmids\": [\"39787234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of microvillar CD20 localization for signaling or cytotoxicity was not established\", \"Whether microvillar enrichment is constitutive or activation-dependent was not resolved\", \"Single-lab methodology awaits independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the molecular identity of the ion conductance pathway regulated by CD20 (intrinsic pore versus activation of a distinct channel), the HDAC6 substrate controlling CD20 mRNA translation, the trans-acting splicing factors governing V1/V3 5′-UTR isoform selection, and the structural basis for CD20's selective requirement in T cell-independent humoral immunity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of apo CD20 dimer without antibody bound\", \"No reconstitution of CD20 ion conductance with defined channel identity\", \"Mechanism linking CD20 to TI-specific B-cell signaling is uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [4, 11, 12]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [14, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 9, 10, 13, 19, 20, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 7, 14, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 11, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [8, 17]}\n    ],\n    \"complexes\": [\n      \"CD20 double-barrel homodimer\"\n    ],\n    \"partners\": [\n      \"BCR (IgM)\",\n      \"CD19\",\n      \"CD53\",\n      \"CD81\",\n      \"CD82\",\n      \"BLNK\",\n      \"SLP-76\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}